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Abstract
Surgical Trial In Traumatic intraCerebral Haemorrhage
(STITCH): a randomised controlled trial of Early Surgery
compared with Initial Conservative Treatment
Barbara A Gregson,1* Elise N Rowan,1 Richard Francis,1
Paul McNamee,2 Dwayne Boyers,2 Patrick Mitchell,1 Elaine McColl,3
Iain R Chambers,4 Andreas Unterberg5 and A David Mendelow1
on behalf of the STITCH(TRAUMA) investigators
1Neurosurgical Trials Group, Institute of Neuroscience, Newcastle University, Newcastle upon
Tyne, UK
2Health Economics Research Unit, University of Aberdeen, Aberdeen, UK
3Newcastle Clinical Trials Unit, Newcastle University, Newcastle upon Tyne, UK
4South Tees Hospitals Foundation Trust, James Cook University Hospital, Middlesbrough, UK
5Department of Neurosurgery, University of Heidelberg, D-69120 Heidelberg, Germany
*Corresponding author barbara.gregson@ncl.ac.uk
Background: While it is accepted practice to remove extradural (EDH) and subdural haematomas (SDH)
following traumatic brain injury, the role of surgery in parenchymal traumatic intracerebral haemorrhage
(TICH) is controversial. There is no evidence to support Early Surgery in this condition.
Objectives: There have been a number of trials investigating surgery for spontaneous intracerebral
haemorrhage but none for TICH. This study aimed to establish whether or not a policy of Early Surgery for
TICH improves outcome compared with a policy of Initial Conservative Treatment.
Design: This was an international multicentre pragmatic parallel group trial. Patients were randomised via
an independent telephone/web-based randomisation service.
Setting: Neurosurgical units in 59 hospitals in 20 countries registered to take part in the study.
Participants: The study planned to recruit 840 adult patients. Patients had to be within 48 hours of head
injury with no more than two intracerebral haematomas greater than 10ml. They did not have a SDH or
EDH that required evacuation or any severe comorbidity that would mean they could not achieve a
favourable outcome if they made a complete recovery from their head injury.
Interventions: Patients were randomised to Early Surgery within 12 hours or to Initial Conservative
Treatment with delayed evacuation if it became clinically appropriate.
Main outcome measures: The Extended Glasgow Outcome Scale (GOSE) was measured at 6 months
via a postal questionnaire. The primary outcome was the traditional dichotomised split into favourable
outcome (good recovery or moderate disability) and unfavourable outcome (severe disability, vegetative,
dead). Secondary outcomes included mortality and an ordinal assessment of Glasgow Outcome Scale and
Rankin Scale.
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Results: Patient recruitment began in December 2009 but was halted by the funding body because of low
UK recruitment in September 2012. In total, 170 patients were randomised from 31 centres in 13 countries:
83 to Early Surgery and 87 to Initial Conservative Treatment. Six-month outcomes were obtained for 99%
of 168 eligible patients (82 Early Surgery and 85 Initial Conservative Treatment patients). Patients in the
Early Surgery group were 10.5% more likely to have a favourable outcome (absolute benefit), but this
difference did not quite reach statistical significance because of the reduced sample size. Fifty-two (63%)
had a favourable outcome with Early Surgery, compared with 45 (53%) with Initial Conservative Treatment
[odds ratio 0.65; 95% confidence interval (CI) 0.35 to 1.21; p= 0.17]. Mortality was significantly higher in
the Initial Conservative Treatment group (33% vs. 15%; absolute difference 18.3%; 95% CI 5.7% to
30.9%; p= 0.006). The Rankin Scale and GOSE were significantly improved with Early Surgery using a trend
analysis (p= 0.047 and p= 0.043 respectively).
Conclusions: This is the first ever trial of surgery for TICH and indicates that Early Surgery may be a
valuable tool in the treatment of TICH, especially if the Glasgow Coma Score is between 9 and 12,
as was also found in Surgical Trial In spontaneous intraCerebral Haemorrhage (STICH) and Surgical Trial
In spontaneous lobar intraCerebral Haemorrhage (STICH II). Further research is clearly warranted.
Trial registration: Current Controlled Trials ISRCTN 19321911.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 19, No. 70.
See the NIHR Journals Library website for further project information.
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Plain English summary
T raumatic intracerebral haemorrhage affects almost a million patients each year worldwide, but the roleof surgery and its timing remain uncertain. This Surgical Trial In Traumatic intraCerebral Haemorrhage
[STITCH(TRAUMA)] has given a strong signal that earlier surgery is advantageous in some patients.
The primary outcome revealed that there is a 10.5% absolute benefit from surgery, but this difference did
not reach statistical significance. This analysis was premature because, at 170 patients, the sample size was
smaller than was originally planned (n= 840) because the study was stopped early by the funding agency
as almost all the study patients were from outside the UK. The effect on mortality was statistically
significant, with the mortality reduced from 33% to 15% (p= 0.007). The other secondary outcome
measures that did reach statistical significance using a trend analysis were the Rankin Scale (p= 0.043)
and the Extended Glasgow Outcome Scale (p= 0.047). This analysis suggests that over 80,000 of these
1 million patients might have their lives saved and have improved outcomes with Early Surgery, but this
urgently needs to be confirmed with a larger trial. The implication for UK patients is that almost 1000 may
be more disabled or die each year than is necessary. The need for another trial is therefore urgent.
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Scientific summary
Background
In the UK there are 1.4 million presentations of head injury at emergency departments each year.
The mortality rate for severe isolated traumatic brain injury varies between 16% and 40%. More than
150,000 of those who present to emergency departments with head injury are admitted to hospital each
year. Of these, about 20,000 injuries are serious. One year after a serious head injury, 35% of patients are
dead or severely disabled. Intracranial haemorrhage occurs in more than 60% of serious head injuries in
one or more of three types: extradural haematoma (EDH), subdural haematoma (SDH) and intracerebral
haemorrhage (ICH). Prompt surgical removal of significant SDH and EDH is of established and widely
accepted value. ICH is more common and is associated with a worse outcome but the role of surgical
removal of the clot remains undefined.
Surgical practice in the treatment of traumatic ICH (TICH) differs widely. Several issues inform the debate:
(a) Contused brain does not recover but appears as encephalomalacic brain tissue loss on convalescent
phase imaging. This suggests that removing TICH does not increase tissue loss.
(b) Extravasated blood is believed to be neurotoxic, leading to secondary injury that may be avoided by
surgical removal.
(c) Larger TICHs may be associated with an ischaemic penumbra of brain tissue that could be salvaged.
(d) Some TICHs expand to the point at which they cause mass effect with high intracranial pressure (ICP),
resulting in secondary brain injury.
The aim of early surgical TICH removal is to prevent secondary brain injury from these mechanisms. Use of
the operation varies around the world. It is more frequently done in the Far East than in Europe or the USA.
Traditional neurosurgical care of patients with severe head injury is frequently based on ICP measurement.
Patients with high ICP (> 30mmHg) and TICH would undergo craniotomy and those with low ICP
(< 20mmHg) would be managed conservatively. Patients with ICP between 20 and 30mmHg would be
observed with ongoing ICP monitoring and undergo craniotomy if the ICP rises. This ICP-based approach
has been recommended by the Brain Trauma Foundation, but has recently been challenged in the Trial of
Intracranial Pressure Monitoring in Traumatic Brain Injury (BEST TRIP) from Latin America. In the light of this
controversy, the early management of patients with TICH needs evaluation to determine if Early Surgery
should become part of the standard of care in the same way it is for significant EDH and SDH.
There have been trials of surgery for spontaneous intracerebral haemorrhage (SICH) but none so far of
surgery for TICH. The Cochrane Review (2nd edition) has shown benefit from surgical evacuation for SICH
(Prasad K, Mendelow AD, Gregson B. Surgery for primary supratentorial intracerebral haemorrhage.
Cochrane Database Syst Rev 2008;4:CD000200). There are differences in the pathogenesis, clinical
behaviour and outcome of the two conditions (SICH and TICH). Patients suffering a TICH tend to be
younger and, therefore, their level of disability may have a larger effect on their ability to return to work
and their economic output. TICHs are more likely to be lobar, to be superficial and to have a medium-sized
volume (25–65 cc). These differences between the conditions mean that we cannot derive the role of
surgery for TICH from SICH trials.
We already know that surgery is effective in patients with traumatic EDH and SDH and that Early Surgery
results in improved outcomes compared with delayed surgery. This is not known for TICH. If Early
Surgery is of benefit to these patients, then implementation of early referral and diagnosis with immediate
treatment may reduce death and disability in this specific group of head-injured patients.
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Several authors have compared surgery with conservative treatment in single-centre retrospective series
and recommended surgery for larger TICHs even if patients were in an apparently good clinical state
initially. None of these studies involved randomisation into surgical and non-surgical groups. They also
differed in the characteristics of the parenchymal blood. Such uncontrolled observational studies may be
potentially misleading and a randomised controlled trial was needed.
Guidelines for the surgical management of traumatic brain injury were published in 2006 in Neurosurgery
(Bullock M, Chesnut R, Ghajar J, Gordon D, Hartl R, Newell D, et al. Surgical management of traumatic
parenchymal lesions. Neurosurgery 2006;58:S25–46; discussion Si–iv). These confirmed that studies in this
area have been observational and that there is a lack of evidence from well-designed randomised
controlled trials. Those studies that attempt to compare outcome between surgical and non-surgical
groups cannot adequately control for unknown prognostic variables.
The National Institute for Health and Care Excellence (NICE) recommended in the Head Injury Update
Full Guideline (2007) (NICE. Clinical Guidelines CG56 Head Injury: Triage, Assessment, Investigation and
Early Management of Head Injury in Infants, Children and Adults. London: NICE; 2007.) that research is
needed to develop a consensus on criteria for lesions not currently considered to be surgically significant,
namely TICH. This trial, Surgical Trial in Traumatic intraCerebral Haemorrhage [STITCH(TRAUMA)], was
recommended by that NICE Head Injury Guideline Development Group.
Objectives
To determine whether or not a policy of Early Surgery in patients with TICH improved outcome compared
with a policy of Initial Conservative Treatment.
To assess the relative costs and consequences of Early Surgery versus Initial Conservative Treatment.
To investigate the use of ICP monitoring for clinical management of head-injured patients with TICH and
its effect on treatment decisions.
Methods
STITCH(TRAUMA) was an international, multicentre, pragmatic, randomised, parallel-group trial comparing
early surgical evacuation of TICH with Initial Conservative Treatment. Only adult patients for whom the
treating neurosurgeon was in equipoise about the benefits of early surgical evacuation compared with
Initial Conservative Treatment were eligible for the trial. Patients had to be within 48 hours of head injury
and to have no more than two TICHs larger than 10ml. They were ineligible if they had a significant
EDH or SDH that required surgery, if a haematoma was located in the cerebellum or if they had a severe
pre-existing physical or mental disability or severe comorbidity that would lead to a poor outcome even
if they made a full recovery from their head injury. An independent 24-hour telephone- and web-based
randomisation service was used. Stratification by country was used together with minimisation by age
and severity with a random component to ensure that the two groups were balanced. Patients were
randomised to Early Surgery (within 12 hours) or to Initial Conservative Treatment. Delayed evacuation
of the haematoma was permitted for patients in the Initial Conservative Treatment group if it became
clinically appropriate. Outcome was measured at 6 months via a postal questionnaire using the Extended
Glasgow Outcome Scale (GOSE).
Additional data were collected in those centres that practised invasive brain monitoring to see if there was
evidence that such monitoring techniques would add value to clinical decision-making. Such monitoring
was not mandatory.
SCIENTIFIC SUMMARY
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The costing analysis was undertaken on the intention-to-treat basis from an international health services
perspective. Resource-use requirements to deliver the interventions (e.g. staff time, overheads) and time
spent on hospital wards were collected using site-specific questionnaires and case report forms. Hospital
readmissions were reported on participant outcome questionnaires. Costing followed recommended
procedures for international studies applying country-specific unit costs (sourced from site-specific
questionnaires) to resource use data to generate total costs. Costs were transformed into 2013
international dollars.
Results
Between December 2009 and September 2012, 170 patients were recruited from 31 centres in
13 countries and randomly assigned to treatment groups: 83 to Early Surgery and 87 to Initial Conservative
Treatment. The study was halted by the funding agency after the recruitment of 170 of the planned
840 patients because of low recruitment in the UK; only six patients had been recruited in the UK. The
study was halted without the funding agency or the study team knowing the outcome despite the Data
Monitoring Committee recommending that it should continue. This study reports results for 82 eligible
patients assigned to Early Surgery and 86 eligible patients assigned to Initial Conservative Treatment.
The distribution of baseline variables between the two treatment groups was very similar. Patients ranged
in age from 16 to 83 years with a median age of 50 years, and 122 (73%) were male. Prior to the head
injury, 164 (98%) had a score on the Rankin Scale of 0 or 1, and 22 (13%) had a medical history of
cardiovascular disease. The main causes of the head injury were road traffic accidents 113 (67%) and falls
47 (28%). Sixty-eight patients (40%) were admitted to another hospital prior to their transfer to the
neurosurgical unit. At the time of randomisation, 70 (42%) patients had a Glasgow Coma Score (GCS) of
13–15, 78 (46%) a GCS of 8–12 and 20 (12%) a GCS of < 8. The volume of the largest haematoma varied
between 10 and 97ml with a median of 23ml, and 61 (36%) patients had a second haematoma between
0 and 26ml with a median of 3ml.
Of the 82 patients in the Early Surgery group, only 61 (74%) had surgery, 57 (93%) of these within
12 hours of randomisation. The reasons for not having surgery were patient or relative refusal (15) or
change in medical status (6). Of the 86 patients randomised to Initial Conservative Treatment, 31 (36%)
had surgery within 14 days of randomisation, 10 (32%) of these within 12 hours. The reasons for having
surgery were neurological deterioration (29) or other (2).
Surgical patients in the Early Surgery group were more likely to have craniotomy than surgical patients in
the Initial Conservative Treatment group (97% vs. 81%; Fisher’s exact test, p= 0.016). Surgical patients
in the Early Surgery group had significantly higher pre-operative GCSs than those requiring surgery in the
Initial Conservative Treatment group. Comparison of the baseline characteristics of patients in the Initial
Conservative Treatment group who had surgery with those who did not showed that patients who
deteriorated and went on to have surgery had larger haematomas initially (Mann–Whitney U-test,
p= 0.010) and were more likely to have at least one pupil unreactive (Fisher’s exact test, p= 0.0005) but
did not differ on age, GCS at the time of randomisation or presence of a second haematoma.
At some point in the first 2 weeks, seven (9%) Early Surgery patients were ICP monitored, compared with
16 (19%) Initial Conservative Treatment patients (p= 0.073), and this affected management decisions in
one Early Surgery patient compared with 10 Initial Conservative Treatment patients (p= 0.069).
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Six-month outcome was available for 82 Early Surgery patients and 85 Initial Conservative Treatment
patients; one patient from the Initial Conservative Treatment group was lost to follow-up. Fifty-two (63%)
Early Surgery patients had a favourable outcome on the dichotomised Glasgow Outcome Scale (GOS),
compared with 45 (53%) Initial Conservative Treatment patients [odds ratio (OR) 0.65, 95% confidence
interval (CI) 0.35 to 1.21; p= 0.171], an absolute difference of 10.5% (95% CI –4.4% to 25.3%).
Adjusting for age, volume and GCS gives an OR of 0.58 (95% CI 0.29 to 1.16; p= 0.122). However, there
was a highly significant difference in mortality at 6 months, with 12 (15%) Early Surgery patients dying,
compared with 28 (33%) Initial Conservative Treatment patients (OR 0.35, 97% CI 0.16 to 0.75;
p= 0.007), and absolute difference of 18.3% (95% CI 5.7% to 30.9%). The Kaplan–Meier plot of survival
for the two groups of patients illustrated the significant advantage of Early Surgery compared with Initial
Conservative Treatment (p= 0.008). The main causes of death were the initial head injury (Early Surgery 5
vs. Initial Conservative Treatment 14) and pneumonia (Early Surgery 4 vs. two Initial Conservative Treatment 2).
This reduction in mortality was not associated with an increase in lower severe dependency and there were no
vegetative survivors in either group.
For each of GOS, GOSE and Rankin Scale at 6 months there was a significant trend in improved outcomes in
the Early Surgery group using the chi-squared trend analysis (p= 0.047, p= 0.052 and p= 0.043
respectively), although the proportional odds models did not reach statistical significance (OR 0.67, 95% CI
0.39 to 1.16, p= 0.153; OR 0.66, 95% CI 0.38 to 1.13, p= 0.127; OR 0.67, 95% CI 0.39 to 1.15, p= 0.147).
None of the pre-specified subgroups displayed any significant heterogeneity of treatment response,
although patients with a GCS of 9–12 exhibited the best response to Early Surgery.
Considering outcome by allocated and received treatment, 33% (20 out of 61) of patients who were
allocated to Early Surgery and had surgery died or were severely disabled at 6 months. However, 65%
(20 out of 31) of patients who were allocated to Initial Conservative Treatment and had delayed surgery
had died or were severely disabled at 6 months, compared with 37% (20 out of 54) of the conservatively
treated patients who did not have surgery.
Patients randomised to the Early Surgery group had an average gain of 0.019 quality-adjusted life-years
(QALYs) over a 6-month period (95% bootstrapped CI –0.004 to 0.043 QALYs), when compared with those
randomised to the Initial Conservative Treatment. This is equivalent to an incremental QALY gain of 3.5 days
over a 6-month period. The broad QALY gains are driven primarily by the increased chance of survival in the
Early Surgery group.
Conclusions
The STITCH(TRAUMA) trial has demonstrated a large reduction in mortality associated with Early Surgery
for parenchymal TICH (p= 0.007) and there were no vegetative survivors. There was not a statistically
significant effect on the pre-specified primary outcome in this reduced sample. However, the observed
10.5% advantage in favourable outcome for the Early Surgery group would have been statistically
significant if it had been maintained for the trial sample size as originally planned. Nevertheless, this was a
very strong signal that Early Surgery will indeed prevent deterioration. This is seen in the improvement
in better outcomes in the ordinal analysis of the GOS and Rankin Scale. A larger trial is urgently needed to
confirm or refute this finding.
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Implications for health care
1. There is a strong case for operating on patients with TICH who have a GCS of 9–12. Those who are
alert or just confused (GCS of 13–15) can probably be watched carefully for any deterioration because
there is a safety margin which diminishes the lower down the GCS the patient descends. Once the GCS
has dropped below 8, surgical intervention appears to be less effective.
2. Based on the results of the study, and the World Health Organization guidelines for cost-effectiveness,
the Early Surgery intervention could be interpreted as offering a high probability of cost-effectiveness in
both high- and upper middle-income countries. There may also be a high probability of cost-effectiveness
in lower middle-income countries, but, based on the cost-effectiveness acceptability curve analysis,
this conclusion would be more sensitive to the threshold value of cost-effectiveness imposed by
decision-makers.
Recommendations for research
This trial has given a very strong signal that Early Surgery is superior to Initial Conservative Treatment for
patients with TICH. This signal was evident despite the sample size being only 20% of that originally
planned. Given that there are 800,000 such injuries each year in the world (8000 per year in the UK
because the UK accounts for 1% of the world’s population of 7 billion), the 10.5% absolute improvement
in favourable outcome represents 84,000 patients every year that could have a better outcome. If this is
true, then the trial needs to be repeated with the utmost urgency to avoid this enormous annual excess
death and disability rate that currently prevails for these patients.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
Much of this text is reproduced from Gregson BA, Rowan EN, Mitchell PM, Unterberg A, McColl EM,Chambers IR, et al. Surgical trial in traumatic intracerebral hemorrhage (STITCH(Trauma)): study
protocol for a randomized controlled trial. Trials 2012;13:193. © 2012 Gregson et al.; licensee BioMed
Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
In the UK there are 1.4 million presentations of head injury at emergency departments each year.1
The mortality rate for severe isolated traumatic brain injury varies between 16% and 40%.2 More than
150,000 of those who present to emergency departments with head injury are admitted to hospital each
year. Of these, about 20,000 injuries are serious. One year after a serious head injury, 35% of patients are
dead or severely disabled. Intracranial haemorrhage occurs in more than 60% of serious head injuries in
one or more of three types: extradural haematomas (EDH), subdural haematomas (SDH) and intracerebral
haemorrhage (ICH). Prompt surgical removal of significant SDH and EDH is of established and widely
accepted value. Intraparenchymal haemorrhage is more common than both the other types put together
and is found in more than 40% of severe head injuries. It is clearly associated with a worse outcome,
but the role of surgical removal of the clot remains undefined. Several terms are used to describe the
condition, including traumatic intracerebral haemorrhage (TICH), traumatic intraparenchymal haemorrhage
and contusion. Prospectively collected data in over 7000 head-injured patients in Newcastle upon Tyne
showed that contusions are more common in older head-injured patients and occurred in patients with
less severe injury.
Surgical practice in the treatment of TICH differs widely. Several issues inform the debate:
(a) Contused brain does not recover but appears as encephalomalacic brain tissue loss on convalescent
phase imaging. This suggests that removing TICH does not increase tissue loss.
(b) Extravasated blood is believed to be neurotoxic, leading to secondary injury that may be avoided by
surgical removal.
(c) Larger TICHs may be associated with an ischaemic penumbra of brain tissue that could be salvaged.
(d) Some TICHs expand to the point at which they cause mass effect with high intracranial pressure (ICP),
resulting in secondary brain injury.
The aim of early surgical TICH removal is to prevent secondary brain injury from these mechanisms.
A detailed description of the pathophysiology of ICH was published in 1993.3 This information translated
into the initial hypothesis that led to the Surgical Trial In spontaneous intraCerebral Haemorrhage (STICH),
which began in 1993.4 This was the justification for a trial of surgical intervention. However, use of the
operation varies around the world. It is more frequently done in the Far East than in Europe or the USA.
Traditional neurosurgical care of patients with severe head injury is frequently based on ICP measurement.
Patients with high ICP (> 30mmHg) and TICH would undergo craniotomy and those with low ICP
(< 20mmHg) would be managed conservatively. Patients with ICP between 20 and 30mmHg would be
observed with ongoing ICP monitoring and undergo craniotomy if the ICP rises.5 This ICP-based approach
has been recommended by the Brain Trauma Foundation6 but its authority has recently been challenged
in the Trial of Intracranial Pressure Monitoring in Traumatic Brain Injury (BEST TRIP) published by Chesnut
et al.7 from Latin America. In the light of this controversy, the early management of patients with TICH
needs evaluation to determine if Early Surgery should become part of the standard of care in the same
way it is for significant EDH8 and SDH.9
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There have been trials of surgery for spontaneous ICH (SICH),4,10 but none so far of surgery for TICH.
The Cochrane Review (2nd edition) has shown benefit from surgical evacuation for SICH.11 There are
differences in the pathogenesis, clinical behaviour and outcome of the two conditions (SICH and TICH).12
Patients suffering a TICH tend to be younger, by about 15 years on average, than patients suffering SICH
and, therefore, the level of disability may have a larger effect on their ability to return to work and their
economic output. TICHs are more likely to be lobar, to be superficial and to have a medium-sized volume
(25–65 cc). These differences between the conditions mean that we cannot derive the role of surgery for
TICH from results of the 15 published trials of surgery for spontaneous ICH; however, the STICH trials4,10
showed a trend towards better outcome with surgery for the group of spontaneous supratentorial ICH
that are most like TICH: superficial haematomas with no intraventricular bleed.
We already know that surgery is effective in patients with traumatic EDH and SDH and that Early Surgery
produces more favourable outcomes than delayed surgery. This is not known for TICH. If Early Surgery is of
benefit to these patients, then implementation of early referral and diagnosis with immediate treatment
may reduce death and disability in this specific group of head-injured patients.
Several authors13–15 have compared surgery with conservative treatment in single-centre retrospective series
and recommended surgery for larger TICHs even if patients were in an apparently good clinical state
initially. Matheisen et al.13 found that patients with an admission Glasgow Coma Score (GCS) of at least 6
and a lesion volume of at least 20ml who had surgery without previous neurological deterioration had
significantly better outcomes than those who did not have surgery or had surgery after deterioration. None
of the patients who had surgery before any deterioration died or was vegetative, as opposed to 39% of
those who had surgery after deterioration and 50% of those who did not have surgery. Choksey et al.14
found that 38% of patients with a low GCS and a volume of the TICH > 16ml who had surgery had a
poor outcome, compared with 56% of those who did not have surgery. Zumkeller et al.15 found that the
poor-outcome rate in the operated patients was 29%, compared with 59% in the non-operated group.
Boto et al.16 evaluated the characteristics of severely head-injured patients with basal ganglia TICHs and
found that the TICH tended to enlarge in the acute post-traumatic period. They found that patients
with a TICH of > 25ml and those in whom TICH enlargement or raised ICP had occurred had the worst
outcomes. They suggested that these patients might benefit from more aggressive surgical treatment.
D’Avella et al.17 published a series and suggested that non-comatose patients with smaller TICHs may be
treated conservatively but that surgery is indicated for patients with larger TICHs. Most of their comatose
patients who were severely injured had a poor outcome whatever treatment was used.
None of these studies involved randomisation into surgical and non-surgical groups. They also differed in
the characteristics of the parenchymal blood. Such uncontrolled observational studies may be potentially
misleading and a randomised controlled trial was needed.
Guidelines for the surgical management of traumatic brain injury were published in 2006.18 These
confirmed that studies in this area have been observational and that there is a lack of evidence from
well-designed randomised controlled trials. Those studies that attempt to compare outcome between
surgical and non-surgical groups cannot adequately control for known prognostic variables.
The National Institute for Health and Care Excellence (NICE) recommended in the Clinical Guidelines CG56
Head Injury: Triage, Assessment, Investigation and Early Management of Head Injury in Infants, Children
and Adults19 that research is needed to develop a consensus on criteria for lesions not currently considered
to be surgically significant, namely TICH. This trial, Surgical Trial in Traumatic intraCerebral Haemorrhage
[STITCH(TRAUMA)], was recommended by that NICE Head Injury Guideline Development Group.
INTRODUCTION
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Chapter 2 Methods
Much of this text is reproduced from Gregson BA, Rowan EN, Mitchell PM, Unterberg A, McColl EM,Chambers IR, et al. Surgical trial in traumatic intracerebral hemorrhage (STITCH(Trauma)): study
protocol for a randomized controlled trial. Trials 2012;13:193. © 2012 Gregson et al.; licensee BioMed
Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Trial objectives
The principal aim of the trial was to determine whether or not a policy of Early Surgery in patients with
TICH improves outcome compared with a policy of Initial Conservative Treatment.
In addition, we wanted to assess the relative costs and consequences of Early Surgery versus Initial Conservative
Treatment in UK patients and those in a subgroup of countries covering the likely highest-recruiting centres.
(Following the trial being halted by the funding agency this objective was changed and reference to a
UK-specific analysis removed.)
Finally, we hoped to confirm appropriate thresholds for ICP and cerebral perfusion pressure (CPP) for clinical
management in the subgroup of head-injured patients with TICH who undergo such monitoring. (Following
the trial being halted by the funding agency this objective was changed to: to investigate the use of ICP
monitoring for clinical management of head-injured patients with TICH and its effect on treatment decisions.)
Trial design
STITCH(TRAUMA) was an international, multicentre, pragmatic, patient-randomised, parallel-group trial
comparing early surgical evacuation of TICH with Initial Conservative Treatment. Only patients for whom
the treating neurosurgeon was in equipoise about the benefits of early surgical evacuation compared with
Initial Conservative Treatment were eligible for the trial. An independent 24-hour telephone randomisation
service based in the Aberdeen Clinical Trials Unit was used and backed by 24-hour availability of trial
investigators who could advise on patient eligibility. Minimisation with a random component was used to
ensure that the two groups were balanced within country, age and severity. Outcome was measured at
6 and 12 months via a postal questionnaire using the Extended Glasgow Outcome Scale (GOSE).
Additional data were collected in those centres that practised invasive brain monitoring to see if there was
evidence that such monitoring techniques added value to clinical decision-making. The aim was to obtain
an unbiased assessment of the effect of clot removal or not on ICP/CPP and to evaluate if monitoring
ICP/CPP provided additional information that informed improved clinical management (the third objective).
Such monitoring was not mandatory for a patient to be enrolled in the trial.
It was planned that relevant health-care costs be assessed in the UK, including length of hospital stay and
the costs associated with surgical treatment (theatre time, consumables, overheads); health-care resource
use outside hospital (e.g. district nurse, physiotherapy) together with productivity costs arising from
absence from work; and additional costs for family members through extra caring responsibilities.
Consequences were to be measured by combining data on quality of life, measured using the European
Quality of Life-5 Dimensions (EQ-5D), with survival to generate quality-adjusted life-years (QALYs). Existing
questionnaires were adapted for use with TICH patients where appropriate, and they formed an additional
3-month postal questionnaire and part of the 6-month and 12-month postal questionnaires for patients.
The trial protocol was published in Trials.20
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Pilot study
An internal pilot phase21 was conducted with criteria for stopping the trial early if the recruitment of
centres and/or patients was slower than projected or if unexpected difficulties arose in signing up
collaborating centres.
The target was not fewer than 12 centres signed up at the end of year 1. If this target was met, then the
pilot was to continue until a second point when the trial had a total of 12 recruiting centre-years. If at this
point the average recruitment rate was less than 2 per centre-year, the trial was to be terminated.
Screening logs
Screening logs were to be maintained by each centre to record the patients admitted to the neurosurgical
unit with any traumatic ICH; whether or not they were eligible for the trial and whether or not they were
recruited (and, if not, why not, if the reason could be ascertained). These were to be used to provide a
context for the study, to monitor recruitment rates and as the basis for constructing the Consolidated
Standards of Reporting Trials (CONSORT) diagram for reporting the trial.
Centre recruitment
Suitable centres were recruited from those already collaborating successfully with the team in other studies
[STICH, Surgical Trial In spontaneous lobar intraCerebral Haemorrhage (STICH II), RESCUEicp] plus those
identified by the various networks: TARN (Trauma Audit and Research Network), EBIC (European Brain Injury
Consortium) and EMN (Euroacademia Multidisciplinaria Neurotraumatologica), BrainIT, EANS (European
Association of Neurosurgical Societies), GNAMED (Glasgow, Newcastle, Aberdeen, Middlesbrough, Edinburgh,
Dundee; Scottish and Newcastle Neurosurgery Research Group), SBNS (Society of British Neurological
Surgeons), BNRG (British Neurosurgery Research Group), ICRAN (International Conference on Recent Advances
in Neurotraumatology) and WFNS (World Federation of Neurosurgical Societies) Neurotrauma Committee.
Centres were required to demonstrate effective trial experience and previous adherence to trial guidelines
with high follow-up rates. In order to be eligible, centres should have been able to recruit a minimum of
one patient per year. They had to be able to communicate with the research team. (At least one member
of the local team had to be proficient in English and provide contact details where they could be reached
easily to support the local centre and respond to the trial management team in Newcastle.) They had to be
able to provide computed tomography (CT) images of sufficient quality to the study centre in Newcastle
and be able to arrange follow-up for patients with limited literacy.
Each centre was required to obtain ethics approval and other permissions as needed to conform with local
and national legislation and governance frameworks and to provide documentary evidence to the trial
management team that these permissions were in place, prior to site registration and initiation. Each site
was also required to sign an agreement with the sponsor (Newcastle upon Tyne Hospitals NHS Foundation
Trust) and the contractor (Newcastle University). Applications by the lead collaborator in each centre for
ethical approval (or Site-Specific Assessment in the UK) were supported by the trial manager and the
clinical lead for the centre and country in which the centre was located. Also within the UK, research and
development approval was sought in respect of all participating centres and the study was open to audit
(‘for cause’ or as part of the routine 10% check) by the appropriate research governance teams in the
participating Trusts. A member of the STITCH(TRAUMA) study team visited centres with high volume
recruitment or where there were concerns about patient eligibility (identified by central monitoring) to
confirm patient existence and monitor adherence to the trial protocol.
METHODS
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Multicentre Research Ethics Committee approval for the study was obtained from Southampton
Multicentre Research Ethics Committee (Reference: 09/H0502/68) on 15 June 2009 and the trial was
registered (ISRCTN19321911).
Patient recruitment
To be considered for STITCH(TRAUMA), patients had to have had CT to confirm the diagnosis and the size
and location of the haematoma. Any clotting or coagulation problems had to be corrected prior to
randomisation in line with standard local clinical practice.
Inclusion criteria
l Adults aged 14 years or over.
l Evidence of a TICH on CT with a confluent volume of attenuation significantly raised above that of
the background white and grey matter that has a total volume greater than 10ml calculated by
(length ×width × height)/2 in cm.22
l Within 24 hours of head injury. This criterion was later increased to 48 hours following discussion at an
investigators’ meeting in order to increase the number of patients eligible, allowing more time for
patients to reach the neurosurgery department and for the TICH to develop.
l Clinical equipoise. Only patients for whom the responsible neurosurgeon was uncertain about the
benefits of either treatment were eligible.
Exclusion criteria
l A significant surface haematoma (EDH or SDH) requiring surgery. (The indications for intervention for
these patients were already very well defined.)
l Three or more separate haematomas fulfilling the inclusion criteria.
l If surgery could not be performed within 12 hours of randomisation.
l Severe pre-existing physical or mental disability or severe comorbidity which would lead to a poor
outcome even if the patient made a full recovery from the head injury. (Examples would be a high level
of dependence before the injury or severe irreversible associated injury such as complete spinal
cord injury.)
l Permanent residence outside a study country preventing follow-up.
l Patient and/or relative having a strong preference for one treatment modality.
There was no specified upper age limit. The need for clinical equipoise and explicit exclusion of patients
with severe pre-existing physical or mental disability or severe comorbidity which might lead to a poor
outcome even if the patient made a good recovery from the head injury excluded the less able older
patient while allowing a fit older person to be included. Haematoma rates were known to be more
common in the older head-injured patient.
Recruitment was encouraged by quarterly glossy newsletters sent to each centre expressing interest,
monthly e-mail newsletters to the site co-ordinators and investigators, regular attendance and
presentations at national and international meetings, having stands at national and international meetings,
sending an e-mail to the investigators and co-ordinators whenever a patient was recruited and awarding
certificates to every surgeon who recruited a patient so that they would be able to demonstrate their
involvement in clinical trials.
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Consent procedure
Written witnessed informed consent of the patient or relative was obtained by trained neurosurgical staff
prior to randomisation. The member of neurosurgical staff provided a written information sheet and
allowed as much time as possible to discuss the options. One copy of the consent form was given to the
patient, one was filed in the patient notes and one was filed with the trial documentation. If the patient
was unable to give consent him- or herself because of the nature of the haemorrhage, a personal
representative was approached to give consent on behalf of the patient. The personal representative was
described as someone with a close personal relationship with the patient who was capable and willing to
consent on behalf of the patient. (If the patient was unable to consent and the closest relative was not
available the patient could not be included in the study. This study did not permit a professional legal
representative to give consent because of the need to establish a relationship with potential carers to
facilitate complete follow-up by postal questionnaire.)
Randomisation (treatment allocation)
Randomisation was achieved via the independent 24-hour randomisation service based in the Aberdeen
Clinical Trials Unit either by telephone or by using the web-based version. The randomisation information was
entered and at the end of the phone call or the web entry the neurosurgeon was informed of the patient
identifier number for the trial and the treatment group the patient was allocated to. The neurosurgeon
recorded this information on the randomisation form and then faxed the form to the STITCH(TRAUMA) office.
The data manager checked the form against the information received from the randomisation centre and
entered the data into an anonymised password-protected database.
The 24-hour randomisation service was backed by 24-hour availability of the project team, who could
advise on patient eligibility. If the site had problems contacting the randomisation service a member of the
project team undertook the randomisation for them.
Allocation was stratified by geographic region, with a minimisation algorithm based on age group
(< 50 years, 50 years to < 70 years, ≥ 70 years) and severity (as measured by whether the pupils are equal
and reacting or not) and with a random component (i.e. with probability of 80%).
Trial interventions
The two trial interventions were early evacuation of the haematoma by a method of the surgeon’s choice
(within 12 hours of randomisation), combined with appropriate best medical treatment versus best medical
treatment combined with delayed (more than 12 hours after randomisation) evacuation if it became
appropriate later. Both groups were monitored according to standard local neurosurgical practice.
Best medical treatment included (depending on the practices within the centre) monitoring of ICP or other
modalities and management of metabolism, sodium osmotic pressure, temperature and blood gases.
All patients also had an additional CT at 5 days (± 2 days) to assess changes in the haematoma size with
and without surgery.
METHODS
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Compliance
Patients or their relatives could withdraw consent for an operation, or, conversely, request an operation,
after randomisation, thereby leading to crossover between the arms. In surgical trials it is common for the
patient’s condition to change over time and a patient randomised to Initial Conservative Treatment might
deteriorate and require surgery later. Such crossovers and the reasons for them were documented.
Information was collected about the status (GCS and focal signs) of patients through the first 5 days of
their trial progress and ICP/CPP measures in invasively monitored patients in order to be able to describe
the change in status that might lead to a change in equipoise for the treating neurosurgeon, and
subsequent surgery in patients initially randomised to conservative treatment.
Compliance with treatment allocation was monitored by the data manager. In surgical trials, patients
allocated to the non-surgical arm of the trial may later deteriorate and surgeons may intervene. This was
the case in the Medical Research Council (MRC)-funded STICH4 and STICH II,10 in trials of cardiac surgery
compared with angioplasty, in the MRC-funded back pain trial23 and in the Spine Patient Outcomes
Research Trial (SPORT).24 These crossover rates to surgery were 26%, 21%, 28%, 28% and 30%
respectively. While surgical trials will always have such crossovers when surgeons perceive that there is
value in operating on patients who deteriorate after initial randomisation into the conservative limb of the
trial, it is important to understand, monitor and report the rates of such crossovers. During the recruitment
of centres and at investigator meetings the importance of clinical equipoise and minimising crossovers
was emphasised and all crossovers were investigated. Centres exhibiting high crossover rates could be
withdrawn from the study.
Data collection
To preserve confidentiality all patients were allocated a unique study identifier during the randomisation
process, which was used on all data collection forms and questionnaires. Only a limited number of
members of the research team were able to link this identifier to patient identifiable details; this was
necessary in order to carry out centralised follow-up.
Baseline
Before randomisation, a one-page baseline form was completed by the responsible neurosurgeon
recording demographic (age, gender) and clot characteristics [site, side, length (A), width (B) and height (C)
measures to define volume] and status at randomisation (GCS, pupils equal and reacting or not).
This information was required in order to randomise the patient.
Two week/discharge
At 2 weeks after randomisation or at discharge or death (whichever occurred first) the discharge/2-week
form was completed. This form recorded the date, the event that triggered the form and the patient’s
status at that time, whether or not the patient had had surgery and when (and why if randomised to Initial
Conservative Treatment or why not if randomised to Early Surgery), the patient’s GCS and localising
features for the 5 days following randomisation, the occurrence of any adverse events (including death,
pulmonary embolism, deep-vein thrombosis, surgical site infection) following randomisation, past medical
history and status prior to the head injury. This form, together with copies of the randomisation CT image
and the 5-day post-randomisation CT image, was sent to the STITCH office within 2 weeks. The data
manager entered the data into the anonymised password-protected database.
Computed tomography
Copies of two CT images were required: the diagnostic CT image prior to randomisation and a 5-day
image. All patients had undergone a diagnostic CT imaging as standard practice. The 5-day image was
due between 3 and 7 days after randomisation. Many patients received this as part of standard treatment
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and the study accepted and used any CT taken for clinical purposes during this period. Only patients who
did not receive such a CT during this period required additional imaging.
The preferred scanning technique was CT with volume acquisition 32 × 0.5mm (or equivalent), 120 kV,
400mA (or equivalent) and 220mm field of view. The preferred angle was parallel with the anterior
cranial fossa, coverage from base of skull to vertex, reconstruct 5mm whole head, soft tissue filter.
The preferred method of sending CT images was in DICOM (Digital Imaging and Communications in
Medicine)-compatible format, on separate CDs for the two time points, anonymised by use of a patient
identifier. They were checked by the data manager initially on receipt at the STITCH(TRAUMA) office to
ensure that the haematoma characteristics at randomisation conformed to the required inclusion criteria.
Where protocol deviations were suspected, the data manager arranged for the image to be viewed by
a trained reader to check whether or not the centre needed to be contacted immediately to
prevent repetitions.
The data manager loaded the images into a specialised password-protected image management program.
They were allocated a separate randomly created identifier by the data manager, so that it would not
be possible for the reader to identify the before-and-after images of the same patient. A separate list
identifying patient identifier and scan identifier was kept by the data manager.
The CT images were to be analysed subsequently by trained readers using the image management
program and a defined protocol. Their passwords gave access only to scans blinded to treatment group
and patient identity.
Follow-up
Postal questionnaires had previously been designed for the STICH4 and STICH II10 studies and were translated
into most of the languages required. Where new countries with different languages were recruited, the National
Investigator was asked to arrange translation and another principal investigator from the country was asked to
check the translation. Postal follow-up was due at 6 months and 12 months. The patient’s general practitioner
(in the UK) or consultant (outside the UK) was contacted at 4.5 months and 10 months to check that the patient
was alive and to confirm his/her place of residence. At that time the clinician was also requested to complete a
major adverse events form to include death, pulmonary embolism, deep-vein thrombosis, stroke or any other
serious adverse event. The 6-month outcome questionnaire was mailed to the patient at 5 months for
completion by the patient or relative if the patient was unable to complete it him- or herself. If necessary, a
reminder was sent at 6 months and telephone follow-up was carried out by ‘blinded’ clerical or nursing staff at
7 months to enhance response rates. Similarly, the 12-month questionnaire was mailed at 11 months with
reminders at 12 and 13 months. In countries where the postal system was poor, patients were requested to
attend a follow-up clinic at which the questionnaire was distributed and collected. In countries where literacy or
language/dialect was a problem, a ‘blinded’ interviewer administered the questionnaire. This methodology had
been developed for use and applied to good effect in STICH and STICH II.
Costs
The costs associated with surgical treatment (theatre time, consumables, overheads) were collected from
published resources and local cost surveys undertaken by the study health economist. Length of stay,
health-care resource use outside hospital, together with productivity costs arising from absence from work,
and additional costs for family members through extra caring responsibilities were collected using the
additional 3-month postal questionnaire and extended 6-month and 12-month postal questionnaires in
the UK. Data were to be combined on quality of life with survival to generate QALYs. This included
measurement of health-care costs, quality of life [EQ-5D-3 level (EQ-5D-3L)] work absence [World Health
Organization (WHO) Health and Performance Questionnaire – Clinical Trial Version] and carer activities
(measured by the discrete choice experiment developed by the Health Economics Research Unit).
EQ-5D-3L and survival were collected for all patients by the postal outcome questionnaires in order to
generate QALYS for the whole study and for a UK-only analysis.
METHODS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
8
Serious adverse events
Serious adverse events were recorded on the Major Adverse Events form. Serious adverse events were
defined as an adverse experience that resulted in any of the following outcomes:
l death
l life-threatening
l inpatient hospitalisation or prolongation of existing hospitalisation
l persistent or significant disability or incapacity.
All serious adverse events were to be reported to the STITCH Office within 7 days of the local investigator
becoming aware of the event and to the local ethics committee or other regulatory bodies as required.
Outcome measures
l Primary: unfavourable outcome was defined as death or severe disability on the Glasgow Outcome
Scale (GOS), which was recorded using a self-completed structured questionnaire based on the
8-point GOS.25
l Secondary: Rankin, EQ-5D-3L, Mortality, Survival, Major Adverse Events (death, pulmonary embolism or
deep-vein thrombosis, infection, rebleeding), QALYs, total health-care costs, social costs.
Structured postal questionnaires were used to collect follow-up data. They contained the GOSE, Rankin
Scale and EQ-5D-3L and were translated into the necessary languages. GOSE and Rankin Scale had been
translated by a national investigator for a previous study and were back-translated to check them. EQ-5D-3L
was obtained in the necessary validated translated versions.
The GOS is the specific measure for head injury and the 8-point scale provides more sensitivity than the
5-point scale. Initially the plan had been to use a prognosis-based26,27 outcome measure such that for
patients with a very poor prognosis an outcome of good recovery, moderate disability or upper severe
disability would be regarded as a favourable outcome, while for patients with a better prognosis a
favourable outcome would be good recovery or moderate disability. Following the withdrawal of funding,
the analysis plan was altered to a simple dichotomised split for all patients. The Rankin Scale is widely used
as a functional outcome measure in stroke and allows comparison of results between this study of patients
with traumatic ICH and studies of patients with spontaneous ICH. EQ-5D-3L is the standard measure of
quality of life incorporating a utility value and has been developed in many languages.
Sample size
Previous studies had suggested a favourable outcome in the non-operated group of about 40% and a
favourable outcome in the surgical group of about 60–70%. However, this was in observational studies.
Given that many randomised controlled trials observe a more favourable outcome than seen in
observational data it was assumed that the favourable outcome (good recovery or moderate disability on
the GOS) in the conservative treatment group would be 50% in order to calculate sample size. A total
sample size of 776 would therefore be required to show a 10% benefit (i.e. 50% vs. 60%) from surgery
(2p< 0.05) with 80% power. A safety margin of 9.5% was built in to allow for loss to follow-up, making
a total sample size of 840 to be recruited and randomised (420 per arm).
In order to achieve this sample size in a reasonable time span and to provide robust evidence, it was
necessary to recruit patients from outside the UK. In England and Wales there are only 30 neurosurgical
units, and only one-third of these participate in randomised controlled trials. Experience with interested
neurosurgical centres in previous studies had shown that about 25% of recruited centres fail to recruit any
patients and a further 25% only recruit one or two patients. The best recruiting centres will recruit about
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9
10 patients per year; therefore, to complete patient recruitment within the time scale, we estimated that
we would need to approach at least 150 centres.
Loss to follow-up was reduced as much as possible. In the previous STICH study, the loss was about 5%.
In STITCH(TRAUMA), the patient population was younger and likely to be more mobile; however,
we implemented procedures that we had developed to minimise loss to follow-up. Methods of follow-up
were adapted to those most likely to be successful within each country and centre according to local
population and care characteristics. Residence in any study country was an eligibility criterion so patients
who suffered a head injury while on holiday would be able to be followed up.
Following the decision by the funding agency to halt the trial, the power of the trial was recalculated.
Using the uncorrected chi-squared test and assuming equal sample sizes in the two groups, and given an
average favourable outcome of 60% (as observed after the recruitment and follow-up of 96 patients),
there would be 26.4% power to detect a 10% difference. The achieved sample size of 170 gave 80%
power to detect a 21% difference.
Blinding
It was not possible to blind either patients or treating surgeons to whether or not the patient had surgery
or when. To minimise possible sources of bias, randomisation was undertaken centrally, thus ensuring
concealment of allocation from the enrolling clinician, patient and relatives. The multidisciplinary team in
the co-ordinating centre and the principal investigators were blinded to the results until after the data set
was locked following receipt of the final outcome questionnaire. Only the data manager and Data
Monitoring Committee (DMC) had access to unblinded data.
Statistical analysis
Initially the primary analysis was planned to be a simple categorical frequency comparison using the
uncorrected chi-squared test for prognosis-based26,27 favourable and unfavourable outcomes at 6 months.
Patients with a good prognosis would be categorised as having a favourable outcome if they achieved
good recovery or moderate disability on the GOS. Patients with a poor prognosis would be categorised as
having a favourable outcome if they achieved good recovery, moderate disability or upper severe disability
on the GOSE. Secondary outcomes were also to be analysed using the prognosis-based method as
specified in STICH.28
However, STITCH(TRAUMA) was halted early by the funding agency for failure to recruit in the UK.
The achieved sample size, at the point when recruitment was halted on instruction from the funding
agency, was 170 patients, with 4% from the UK. The analysis plan was, therefore, adapted from the
original analysis statement published in the protocol20 in the light of this much reduced sample size.
The new plan was developed and published on the study website without access to treatment allocation
prior to unblinding the data.
Primary outcome
Analysis was on an intention-to-treat basis. The primary analysis was a simple categorical frequency
comparison using the uncorrected chi-squared test for favourable and unfavourable outcomes at 6 months.
Patients were categorised as having a favourable outcome if they achieved good recovery or moderate
disability on the GOS. Patients were categorised as having an unfavourable outcome if they had severe
disability on the GOS, were vegetative or had died. A sensitivity analysis using logistic regression was
undertaken to adjust for age, volume of haematoma and GCS.
METHODS
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Secondary outcomes
Secondary outcome analyses included the proportional odds model analysis of GOS, GOSE and Rankin
Scale scores at 6 months, Kaplan–Meier survival curve with log-rank test, mortality at 6 months and
dichotomised Rankin Scale score (0–2, 3–6) at 6 months (comparing patients able to look after their own
affairs with patients who need help). For dichotomised outcomes, absolute differences and 95%
confidence intervals (CIs) were reported. Secondary outcomes were also collected at 12 months but were
not required by the funding agency.
Subgroup analysis
Minimal subgroup analysis was undertaken and regarded as exploratory. Odds ratios (ORs) and 95% CIs
were reported for the following subgroups: age (two bands using randomisation strata: < 50 years and
≥ 50 years – there were very few patients aged over 70 years so the two upper age bands were combined),
volume of haematoma (using median split: ≤ 23ml, > 23ml), GCS (using standard classification of head
injury severe, moderate, minor: 3–8, 9–12, 13–15), time from ictus to randomisation (using median split
< 21 hours, ≥ 21 hours) and geographical region (four bands: Europe, India, China, other). Interaction tests
(chi-squared test for heterogeneity) were undertaken and relevant p-values reported.
Protocol violations
There were two cases of major protocol violation in that the treatment decision was taken prior to
randomisation. One patient randomised to surgery had already had a decision made for no surgery to take
place and one case randomised to Initial Conservative Treatment had already had surgery. These two cases
will be excluded from all analyses.
Health economics analysis
A cost–utility analysis was conducted from a health service perspective and based on an intention-to-treat
principle.
Health-care resource use data were sourced from individual case report forms and participant questionnaires
and supplemented using additional questionnaires administered to a sample of trial recruiting centres.
Standard unit cost estimates were applied to resource use data for intervention delivery, hospital length of
stay and rehospitalisation. Where standard unit costs were not available, supplemental information was
collected from the additional questionnaire (e.g. cost of an hour of a surgeon’s time) and WHO choice data
for the cost per night in hospital. Intervention and follow-up costs were summed to generate total costs to
the health services for each individual within the trial. Costing followed recommended procedures for
international studies29,30 and costs were transformed into 2013 international dollars.31 Standard general
linear regression methods were used to estimate the impact of treatment group (conservative or Early
Surgery) on costs. Estimates were calculated for all countries as well as country subgroups classified
according World Bank classifications32 based on gross national income (GNI) per capita as follows:
low income (GNI ≤ Int$1005, e.g. Nepal), lower middle income (GNI Int$1006–3975, e.g. India), upper
middle income (GNI Int$3976–12,275, e.g. China), and high income (GNI ≥ Int$12,276, e.g. Western
Europe, USA). Owing to small sample sizes, regression analyses were not undertaken.
Reporting statistics
For categorical variables, the number and percentage in each group are reported. Percentages are reported
to no decimal places. For continuous variables, the median, quartiles, maximum and minimum are
reported. Where p-values are reported, these are given to three decimal places or to one significant figure
if four decimal places are required and then < 0.0001 if smaller still. The absence of data is reported.
Outcomes are reported as ORs with 95% CIs and to two decimal places and p-values to three decimal
places. Absolute benefits with 95% CIs to one decimal place are also reported.
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Research governance
To conform with the Research Governance Framework for Health and Social Care, the role of sponsor for
this study was taken on by the Newcastle upon Tyne Hospitals Foundation NHS Trust. All study-attached
staff were appropriately qualified and trained in Good Clinical Practice appropriate to their role in
the study.
Trial Steering Committee
Independent oversight of the study was provided by a Trial Steering Committee (TSC). The TSC met at
6-monthly intervals during the study. It provided overall supervision of the trial on behalf of the Health
Technology Assessment (HTA) programme. It considered progress of the trial (in particular, success in site
and patient recruitment), adherence to the protocol, patient safety and consideration of new information.
The trial was conducted according to the standards set out in the MRC Guidelines for Good Clinical Practice.
Data Monitoring Committee
In order to monitor accumulating data on patient safety and treatment benefit, a DMC was established.
The DMC considered data from interim analyses after 50, 100 and 150 patients had been recruited. It
reported to the TSC. Interim analyses were strictly confidential and the committee would recommend
stopping the trial early only if one or other treatment showed an advantage at a very high significance
level or if the recruitment rates were unexpectedly low. The DMC recommended at each review that the
trial should continue.
Management committee
This group met weekly to monitor progress and compliance. On a quarterly basis, funnel plots showing the
proportion of patients who had died by the number recruited per site and the proportion of crossovers
were reported to the group.
National Investigators
In countries with multiple centres, one centre investigator was required to fulfil the role of National
Investigator and be responsible for obtaining national ethics approval and other permissions as required,
for ensuring that documentation was translated from English as required, for identifying suitable centres
within their country, for encouraging recruitment and for acting as a liaison person between the
management team and the centres if required.
Centre investigators
Each centre had a centre investigator responsible for the conduct of the trial in that centre.
Patient and public involvement
There are two main charities involved with head injury research in the UK: Headway and UK Acquired
Brain Injury Forum. Both organisations were invited to propose representatives to sit on the TSC. These
representatives supported the study, providing advice on all aspects of the trial including design of the
questionnaires, changes in the protocol and recruitment to the study.
METHODS
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Chapter 3 Results
Timelines
Funding was activated on 1 September 2009 and the first site opened to recruitment on 1 October 2009. The
first patient was recruited in December 2009. In March 2012, the HTA programme announced that it would
be withdrawing funding because of the low UK recruitment. It felt that the study was not viable in the UK
and that there was no realistic chance of that changing in the near future. It did agree to a managed process
of withdrawal, particularly for non-UK centres, to enable the project team to investigate the possibility of
support from another funder in order to continue the trial and to fulfil the ethical responsibility for follow-up
of current study participants and maximise data available for future meta-analyses. Despite considerable
efforts to identify further funding both in the UK and abroad, the project team were unsuccessful in achieving
this in the short time available and the final patient was recruited by 30 September 2012.
Centre recruitment
Interest in the study was expressed by 139 centres, and 59 of these completed all the regulatory requirements
to become registered centres. The registered centres were located in 20 countries: the UK (n= 9), Armenia
(n= 1), Bulgaria (n= 1), Canada (n= 1), the People’s Republic of China (n= 3), the Czech Republic (n= 1),
Egypt (n= 2), Germany (n= 6), Hungary (n= 1), India (n= 14), Italy (n= 1), Latvia (n= 1), Lithuania (n= 2),
Malaysia (n= 2), Nepal (n= 1), Pakistan (n= 1), Romania (n= 3), Russia (n= 1), Spain (n= 2) and the
USA (n= 6). A further 13 centres had obtained ethical approval but were unable to complete the regulatory
processes prior to the study being halted. Figure 1 shows the accumulation of centres through the trial.
Regulatory processes are difficult and time-consuming and the difficulties in recruiting centres to surgical trials
have been reported previously.33 The times to recruitment for individual centres are shown in Figure 2 and the
variability within countries in Figure 3.
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FIGURE 1 Recruitment of centres over time.
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Screening logs
Screening logs were returned by 32 centres from 15 countries, covering 251 centre-months out of a
potential 1028 centre-months. The logs reported 1735 patients screened, of whom 1542 were reported to
be ineligible, 134 eligible but not included and 59 recruited. The main reasons for ineligibility were that
the ICH was too small (49%) or that the patient had an EDH or SDH that required surgery (20%). Reasons
for not recruiting eligible patients included no consent (77%) and failure to randomise (23%). Further
descriptions of these data are given in Francis et al.34
Patient recruitment
Between December 2009 and September 2012, 170 patients were recruited from 31 centres in 13
countries and randomly assigned to treatment groups: 83 to Early Surgery and 87 to Initial Conservative
Treatment (Figure 4). After an initial slow recruitment phase, when the number of centres recruiting was
low, the rate of recruitment picked up and in fact matched the recruitment seen in a previous SICH study.
However, announcement of the plan to withdraw funding resulted in a slowdown in recruitment even
though it continued for a further 6 months. This was probably a result of trial fatigue and a decision by the
trial team not to encourage further centre recruitment until attempts to obtain further funding had
been exhausted.
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Figure 5 shows recruitment by centre and country. India was the highest-recruiting country, with a total of
74 patients, followed by China with 43. There were 27 patients recruited in Europe, including six in the UK,
and 26 in the other countries (Pakistan, Malaysia, Nepal and Egypt).
Figure 6 shows the CONSORT diagram for the trial. Two patients were excluded because the treatment
decision was made prior to randomisation: in one case the patient was operated on prior to randomisation
and in the other a decision was made not to operate prior to randomisation. These were serious protocol
violations. All other patients were included in the analysis. Only one patient was lost to 6-month follow-up.
This report therefore reports baseline measures for 168 patients and results for 167 patients, 82 patients
assigned to Early Surgery and 85 patients assigned to Initial Conservative Treatment.
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Allocated to Early Surgery (n = 83) Allocated to Initial Conservative Treatment (n = 87)
Allocation
Baseline
Randomised (n = 170)
Allocated to Initial Conservative Treatment (n = 86)
• Received allocated intervention, n = 55
• Did not receive allocated intervention, n = 31
Allocated to Early Surgery (n = 82)
• Received allocated intervention, n = 61
• Did not receive allocated intervention, n = 21
Followed up at 6 months (n = 82) Followed up at 6 months (n = 85)
Analysed at 6 months (n = 82) Analysed at 6 months (n = 85)
6-month follow-up
Primary outcome analysis
Exclude (n = 1) a site decided not to
operate before randomisation
Exclude (n = 1) a site operated
before randomisation
Screened
Sites completing logs
Assessed for eligibility (n = 1735)
Sites not completing logs
Assessed for eligibility (n = NK)
Consented (n = 59) Consented (n = 111)
Not eligible (n = 1542)
No equipoise (n = 31)
Refused consent (n = 103)
Lost to follow-up (n = 0) Lost to follow-up (n = 1)
FIGURE 6 Consolidated Standards of Reporting Trials flow chart for STITCH(TRAUMA) patients. NK, not known.
a, One site recruited one patient but had undertaken surgery prior to randomisation; the patient was allocated
to Initial Conservative Treatment. Another site recruited one patient for whom a treatment decision not to
operate was made before the patient was randomised; this patient was allocated to Early Surgery. Because
of the severe breach of protocol, these patients were excluded. Reproduced from Mendelow et al.35
© A. David Mendelow, Barbara A. Gregson, Elise N. Rowan, Richard Francis, Elaine McColl, Paul McNamee,
Iain R. Chambers, Andreas Unterberg, Dwayne Boyers, and Patrick M. Mitchell 2015; Published by Mary Ann
Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons License
(http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly credited.
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Baseline measures
Tables 1–6 show the distribution of baseline variables between the two treatment groups. Patients ranged in
age from 16 to 83 years, with a median age of 50 years, and 122 (73%) were male (Table 1). Despite 13%
of patients being over the age of 70 years, only 7% were on any anticoagulant or antiplatelet medication.
Prior to the head injury, 164 patients (98%) scored 0 or 1 on the Rankin Scale, and 22 (13%) had a medical
history of cardiovascular disease (Table 2). The main causes of the head injury were road traffic accidents
(113, 67%) and falls (47, 28%) (Table 3). Most of those who were in a road traffic accidents were motorbike
riders (n= 45, 40%) or pedestrians (n= 29, 26%). Patients from Europe were most likely to have suffered a
fall (74%) while patients from Asia were most likely to have had a road traffic accident (76%) either on a
motorbike or as a pedestrian.
Sixty-eight (40%) patients were admitted to another hospital prior to their transfer to the neurosurgical unit,
and the time from injury to randomisation varied between 3 and 48 hours with a median of 22 hours
(Table 4). Two-thirds (n= 111; 66%) had an initial loss of consciousness, 25 (15%) pretraumatic amnesia and
41 (24%) post-traumatic amnesia.
TABLE 1 Baseline variables: age, sex, pre-injury status
Variable Early Surgery (N= 82) Initial Conservative Treatment (N= 86)
Age (years)
Median (IQR) 51 (32–63) 50 (33–61)
Range 18–83 16–77
Mean (SD) 48 (17.7) 48 (16.9)
Age band (years), n (%)
< 50 37 (45) 42 (49)
50–69 34 (42) 33 (38)
≥ 70 11 (13) 11 (13)
Sex, n (%)
Male 57 (70) 65 (76)
Female 25 (30) 21 (24)
Pre-ICH Rankin Scale score, n (%)
0 74 (90) 78 (91)
1 6 (7) 6 (7)
2 2 (2) 0 (0)
3 0 (0) 1 (1)
4 0 (0) 0 (0)
5 0 (0) 1 (1)
Pre-ICH mobility, n (%)
Able to walk 200m 80 (98) 82 (95)
Able to walk indoors 1 (1) 3 (3)
Unable to walk 1 (1) 1 (1)
Handedness,a n (%)
Right 80 (98) 84 (99)
Left 2 (2) 1 (1)
IQR, intraquartile range; SD, standard deviation.
a Handedness was not recorded for one patient in the Initial Conservative Treatment group.
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TABLE 2 Baseline variables: medical history
Variable Early Surgery, n (%) (N= 82) Initial Conservative Treatment, n (%) (N= 86)
Significant medical history
Cardiovascular 10 (12) 12 (14)
Gastrointestinal 4 (5) 3 (3)
Musculoskeletal 3 (4) 1 (1)
Oncological 1 (1) 1 (1)
Renal 1 (1) 0 (0)
Epilepsy 2 (2) 2 (2)
Endocrine 4 (5) 5 (6)
Haematological 2 (2) 0 (0)
Neurological 0 (0) 3 (3)
Pulmonary 1 (1) 1 (1)
Social history 3 (4) 3 (3)
Antiepileptics 1 (1) 2 (2)
ENT 1 (1) 2 (2)
Hepatic 2 (2) 2 (2)
Previous TBI 1 (1) 2 (2)
Psychiatric 0 (0) 0 (0)
Developmental 0 (0) 0 (0)
Prior to ICH anticoagulant 2 (2) 0 (0)
Prior to ICH antiplatelet 3 (4) 7 (8)
Prior to ICH thrombolytic 0 (0) 0 (0)
ENT, ear, nose and throat; TBI, traumatic brain injury.
TABLE 3 Injury causes and mechanisms
Variable Early Surgery, n (%) (N= 82) Initial Conservative Treatment, n (%) (N= 86)
Cause of injury
Road traffic accident 54 (66) 59 (69)
Fall domestic 15 (18) 15 (17)
Fall outside home 8 (10) 9 (10)
Work 0 (0) 1 (1)
Violence/assault 3 (4) 2 (2)
Animal attack 2 (2) 0 (0)
Mechanism of injurya
Acceleration/deceleration 13 (16) 23 (28)
Direct impact 38 (47) 25 (30)
Crush 2 (2) 1 (1)
Fall from ground 18 (22) 26 (31)
Fall from height 8 (10) 8 (10)
Fall (details unknown) 2 (2) 0 (0)
a Data missing for mechanism of injury (n= 4 cases).
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TABLE 4 Emergency service therapeutic procedures and hospital admission details
Variable Early Surgery (N= 82) Initial Conservative Treatment (N= 86)
Time to randomisation (hours)
Median (IQR), range 21 (13–31), 3–48 22 (14–28), 4–48
Mean (SD) 22 (11.7) 22 (10.6)
Emergency services provided for the airway, n (%)
None 28 (34) 21 (24)
Oxygen 45 (55) 56 (65)
Intubation 6 (7) 8 (9)
Oxygen and intubation 3 (4) 1 (1)
Site of additional injuries, n (%)
Skin 35 (43) 46 (53)
Head and neck 63 (77) 67 (78)
Face 34 (41) 37 (43)
Chest 11 (13) 11 (13)
Abdomen 7 (9) 1 (1)
Extremities 17 (21) 11 (13)
Spine 3 (4) 2 (2)
Initial loss of consciousness, n (%)
Yes 57 (70) 54 (63)
No 15 (18) 20 (23)
Unknown 10 (12) 12 (14)
Pre-traumatic amnesia, n (%)
Yes 16 (20) 9 (10)
No 33 (40) 40 (47)
Unknown 33 (40) 37 (43)
Post-traumatic amnesia, n (%)
Yes 22 (27) 19 (22)
No 27 (33) 34 (40)
Unknown 33 (40) 33 (38)
Secondary insults, n (%)
Hypoxic 3 (4) 3 (3)
Hypotensive 2 (2) 2 (2)
Hypothermic 0 (0) 0 (0)
Cardiac arrest 0 (0) 0 (0)
Referral details, n (%)
Primary admission 45 (55) 55 (64)
Secondary admission 37 (45) 31 (36)
IQR, intraquartile range; SD, standard deviation.
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The volume of the largest haematoma varied between 10ml and 97ml, with a median of 23ml, and
61 (36%) patients had a second haematoma between 0ml and 26ml, with a median of 3ml (Table 5).
All of the reported haematomas were located in the lobar regions of the brain, particularly in the frontal or
temporal areas. The distribution of baseline variables between the two groups was very similar. At the time
of randomisation, 70 (42%) patients had a GCS of 13–15, 78 (46%) a GCS of 8–12 and 20 (12%) a GCS
of < 8 (Table 6). More than 85% of patients had a motor score on the GCS of 5 or more.
Surgery
Of the 82 patients in the Early Surgery group, only 61 (74%) had surgery, 57 (93%) of these within
12 hours of randomisation (Table 7). The reasons for not having surgery were patient or relative refusal
(n= 15), improvement (n= 1), deterioration (n= 2), seizures (n= 1), anaesthetic risk (n= 1) and change
of history suggesting spontaneous rather than traumatic ICH (n= 1). Although informed consent was
obtained prior to randomisation, patients often had more than one relative and further discussion could
lead to a change of opinion.
TABLE 5 Haematoma characteristics
Variable Early Surgery (N= 82) Initial Conservative Treatment (N= 86)
Volume of largest haematoma (ml)
Median (IQR), range 25 (18–37), 11–96 23 (15–32), 10–97
Mean (SD) 31 (18.0) 27 (16.8)
Location of largest haemorrhage, n (%)
Frontal 36 (44) 43 (50)
Temporal 39 (48) 37 (43)
Parietal 4 (5) 5 (6)
Occipital 3 (4) 1 (1)
Second haematoma present, n (%)
Yes 28 (34) 33 (38)
No 54 (66) 53 (62)
Volume of second haematoma if applicable (ml)
Median (IQR), range 3 (1–10), 0–20 4 (2–8), 0–26
Mean (SD) 6 (6.3) 6 (6.6)
Location of second haemorrhage, n (%)
Frontal 20 (24) 15 (17)
Temporal 6 (7) 12 (14)
Parietal 1 (1) 6 (7)
Occipital 1 (1) 0 (0)
No second haemorrhage 54 (66) 53 (62)
IQR, intraquartile range; SD, standard deviation.
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TABLE 6 Baseline variables: status at randomisation
Variable Early Surgery, n (%) (N= 82) Initial Conservative Treatment, n (%) (N= 86)
GCS: eye
1 7 (9) 12 (14)
2 21 (26) 17 (20)
3 23 (28) 25 (29)
4 31 (38) 32 (37)
GCS: verbal
1 12 (15) 15 (17)
2 21 (26) 19 (22)
3 8 (10) 14 (16)
4 23 (28) 20 (23)
5 18 (22) 18 (21)
GCS: motor
1 0 (0) 1 (1)
2 2 (2) 1 (1)
3 4 (5) 5 (6)
4 6 (7) 4 (5)
5 32 (39) 33 (38)
6 38 (46) 42 (49)
GCS: total
3 0 (0) 1 (1)
4 0 (0) 0 (0)
5 1 (1) 2 (2)
6 6 (7) 3 (3)
7 4 (5) 3 (3)
8 1 (1) 6 (7)
9 11 (13) 8 (9)
10 11 (13) 14 (16)
11 6 (7) 8 (9)
12 6 (7) 7 (8)
13 10 (12) 8 (9)
14 14 (17) 13 (15)
15 12 (15) 13 (15)
Pupils
Both reactive 77 (94) 79 (92)
One reactive 3 (4) 3 (3)
Both unreactive 2 (2) 4 (5)
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TABLE 7 Surgery details
Variable
Early Surgery: surgical cases only,
N= 61 (74%)
Initial Conservative Treatment:
surgical cases only, N= 31 (36%)
Method, n (%)
Craniotomy 59 (97) 25 (81)
Other 2 (3) 6 (19)
Other surgical details
Bone flap replaced 47 (77) 13 (42)
Other cranial surgery 1 (2) 3 (10)
Paralysed and sedated 17 (28) 12 (39)
Any non-cranial surgery 1 (2) 2 (7)
Pre-operative GCS: eye, n (%)
1 5 (8) 15 (48)
2 18 (30) 8 (26)
3 19 (31) 5 (16)
4 19 (31) 3 (10)
Pre-operative GCS: verbal, n (%)
1 13 (21) 16 (52)
2 15 (25) 7 (23)
3 6 (10) 5 (16)
4 18 (30) 0 (0)
5 9 (15) 3 (10)
Pre-operative GCS: motor, n (%)
1 0 (0) 4 (13)
2 2 (3) 1 (3)
3 6 (10) 3 (10)
4 4 (7) 6 (19)
5 26 (43) 14 (45)
6 23 (38) 3 (10)
Time randomisation to surgery (hours)
Median (IQR), range 3 (1–6), < 1–24 25 (6–79), < 1–318
Mean (SD) 4 (4.5) 58 (75.6)
Surgery within 12 hours of randomisation,
n (%)
57 (93) 10 (32)
Time injury to surgery (hours)
Median (IQR), range 23 (16–36), 4–69 45 (26–99), 9–332
Mean (SD) 26 (13.8) 78 (79.0)
Surgery within 12 hours of injury, n (%) 9 (15) 3 (10)
IQR, intraquartile range; SD, standard deviation.
Reproduced from Mendelow et al.35 © A. David Mendelow, Barbara A. Gregson, Elise N. Rowan, Richard Francis,
Elaine McColl, Paul McNamee, Iain R. Chambers, Andreas Unterberg, Dwayne Boyers, and Patrick M. Mitchell 2015;
Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons
License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly credited.
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Of the 86 patients randomised to Initial Conservative Treatment, 31 (36%) had surgery within 14 days
of randomisation, 10 (32%) of these within 12 hours. The reasons for having surgery were neurological
deterioration (n= 29), no shrinkage in haematoma size (n= 1) and rise in ICP (n= 1). Neurological
deterioration was identified by a drop in GCS, enlargement of the haematoma or increase in midline shift,
increase in weakness or change in pupil size or reactivity.
Surgical patients in the Early Surgery group were more likely to undergo craniotomy than surgical patients
in the Initial Conservative Treatment group (97% vs. 81%; Fisher’s exact test, p= 0.016). One patient in
the Initial Conservative Treatment group underwent burrhole surgery, but all other patients who did not
have craniotomy underwent craniectomy. The bone flap was more likely to be replaced in the surgical
patients in the Early Surgery group (77%) than in the Initial Conservative Treatment group (42%)
(Fisher’s exact test, p= 0.001). As Table 3 demonstrates, surgical patients in the Early Surgery group had
significantly higher pre-operative GCS values on all the subscales than those requiring surgery in the Initial
Conservative Treatment group. Comparison of the baseline characteristics of patients in the Initial Conservative
Treatment group who had surgery with those who did not showed that patients who deteriorated and went
on to have surgery had larger haematomas initially (Mann–Whitney U-test, p= 0.010) and were more likely to
have at least one pupil unreactive (Fisher’s exact test, p= 0.0005) but did not differ on age, GCS at the time
of randomisation or presence of a second haematoma.
Hospital stay
At 2 weeks post randomisation, similar proportions of patients in the two groups were still on the
neurosurgical ward: 29 (35%) of the Early Surgery patients and 32 (37%) of the Initial Conservative
Treatment patients. The proportions that had been transferred to another ward or hospital were also
similar: three (4%) and four (5%) respectively. However, 43 (52%) Early Surgery patients had been
discharged, compared with 33 (38%) Initial Conservative Treatment patients. Furthermore, there was a
significant difference in the percentage of patients who had died by 2 weeks: 7 (9%) Early Surgery
patients compared with 17 (20%) Initial Conservative Treatment patients (Fisher’s exact test, p= 0.047).
At some point in the first 2 weeks, ICP was monitored in seven (9%) Early Surgery patients, compared
with 16 (19%) Initial Conservative Treatment patients (p= 0.073), and this affected management decisions
in one Early Surgery patient, compared with 10 Initial Conservative Treatment patients (p= 0.069) (Table 8).
Patients were less likely to be monitored in India, where the rate was 4% (3 out of 74), compared with
21% elsewhere (20 out of 94).
Very few postrandomisation events were recorded during the first 2 weeks of the hospital stay (Table 9).
The most frequently reported was pneumonia, with eight Early Surgery patients and eight Initial
Conservative Treatment patients.
Primary outcome
Six-month outcome was available for 82 Early Surgery patients and 85 Initial Conservative Treatment
patients; one patient from the Initial Conservative Treatment group was lost to follow-up. Fifty-two (63%)
Early Surgery patients had a favourable outcome on the dichotomised GOS, compared with 45 (53%)
Initial Conservative Treatment patients (OR 0.65, 95% CI 0.35 to 1.21; p= 0.171): an absolute difference
of 10.5% (95% CI –4.4% to 25.3%) (Table 10). Adjusting for age, volume and GCS gave an OR of 0.58
(95% CI 0.29 to 1.16; p= 0.122).
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TABLE 8 Intracranial pressure monitoring frequency and details
Variables Early Surgery, n (%) (N= 82) Initial Conservative Treatment, n (%) (N= 86)
ICP monitored
Yes 7 (9) 16 (19)
No 75 (91) 70 (81)
Monitor type (of ICP-monitored cases)
Intraventricular 0 (0) 1 (6)
Camino 3 (43) 5 (31)
Codman 2 (29) 7 (44)
Spiegelberg 2 (29) 3 (19)
Monitoring affected management (of ICP-monitored cases)
Yes 1 (14) 10 (63)
No 6 (86) 6 (37)
TABLE 9 Deaths and post randomisation events recorded on the 2-week form
Variable Early Surgery, n (%) (N= 82) Initial Conservative Treatment, n (%) (N= 86)
Death 7 (9) 17 (20)
Ischaemic stroke 0 (0) 1 (1)
Pulmonary embolism 1 (1) 2 (2)
Deep-vein thrombosis 0 (0) 0 (0)
Pneumonia 8 (10) 8 (9)
Postoperative EDHa 0 (0) 2 (2)
Septicaemia 1 (1) 0 (0)
Urinary tract infectiona 1 (1) 0 (0)
Epilepsy 3 (4) 0 (0)
Other 5 (6) 1 (1)
a Data missing on one case.
TABLE 10 Primary outcome at 6 months
Primary outcome
(prognosis-based)
Early Surgery,
n (%) (N= 82)
Initial Conservative Treatment,
n (%) (N= 85)
Test and p-value, absolute
difference (95% CI)
Unfavourable 30 (37) 40 (47) Chi-squared test, p= 0.170,
10.5% (–4.4% to 25.3%)
Favourable 52 (63) 45 (53)
Reproduced from Mendelow et al.35 © A. David Mendelow, Barbara A. Gregson, Elise N. Rowan, Richard Francis,
Elaine McColl, Paul McNamee, Iain R. Chambers, Andreas Unterberg, Dwayne Boyers, and Patrick M. Mitchell 2015;
Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons
License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly credited.
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Secondary outcomes
However, there was a highly significant difference in mortality at 6 months, with 12 (15%) Early Surgery
patients dying compared with 28 (33%) Initial Conservative Treatment patients (OR 0.35, 95% CI 0.16 to
0.75, p= 0.007): absolute difference 18.3% (95% CI 5.7% to 30.9%) (Table 11). Figure 7 shows the
Kaplan–Meier plot of survival for the two groups of patients, illustrating the significant advantage of Early
Surgery compared with Initial Conservative Treatment (p= 0.008).
TABLE 11 Secondary outcomes at 6 months
Variable
Early Surgery,
n (%) (N= 82)
Initial Conservative Treatment,
n (%) (N= 85)
Test and p-value, absolute
difference (95% CI)
Mortality at 6 months
Dead 12 (15) 28 (33) Chi-squared test, p= 0.006,a
18.3 (5.7 to 30.9)
Alive 70 (85) 57 (67)
GOS
Dead 12 (15) 28 (33) Chi-squared test trend, p= 0.047,a
POM, p= 0.153
Vegetative 0 (0) 0 (0)
Severely disabled 18 (22) 12 (14)
Moderately
disabled
26 (32) 18 (21)
Good recovery 26 (32) 27 (32)
GOSE
Dead 12 (15) 28 (33) Chi-squared test trend, p= 0.052,
POM, p= 0.127
Vegetative 0 (0) 0 (0)
Lower SD 4 (5) 8 (9)
Upper SD 14 (17) 4 (5)
Lower MD 5 (6) 3 (4)
Upper MD 21 (26) 15 (18)
Lower GR 12 (15) 12 (14)
Upper GR 14 (17) 15 (18)
Dichotomised Rankin Scale score
Unfavourable 27 (33) 37 (44) Chi-squared test, p= 0.159,
10.6 (–4.0 to 25.3)
Favourable 55 (67) 48 (56)
Rankin Scale score
0 17 (21) 18 (21) Chi-squared test trend, p= 0.043,a
POM, p= 0.147
1 27 (33) 22 (26)
2 11 (13) 8 (9)
3 8 (10) 4 (5)
4 7 (9) 3 (4)
5 0 (0) 2 (2)
Dead 12 (15) 28 (33)
continued
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TABLE 11 Secondary outcomes at 6 months (continued )
Variable
Early Surgery,
n (%) (N= 82)
Initial Conservative Treatment,
n (%) (N= 85)
Test and p-value, absolute
difference (95% CI)
EQ-5D index
Median 0.80 0.71 Mann–Whitney U-test, p= 0.218
IQR 0.52–1.00 0.00–1.00
Range –0.33 to 1.00 –0.59 to 1.00
Limb movement
Worse-affected legb
Unaffected 50 (72) 47 (82) Chi-squared test, p= 0.374
Weak 18 (26) 9 (16)
Paralysed 1 (1) 1 (2)
Worse-affected armb
Unaffected 48 (70) 43 (75) Chi-squared test, p= 0.464
Weak 21 (30) 14 (25)
Paralysed 0 (0) 0 (0)
GR, good recovery; IQR, interquartile range; MD, moderate disability; POM, proportional odds model; SD, severe diability.
a Statistically significant.
b One patient did not provide information about their limb movements.
EQ-5D utility index calculated using UK weightings provided by the EuroQol Group Foundation.
Reproduced from Mendelow et al.35 © A. David Mendelow, Barbara A. Gregson, Elise N. Rowan, Richard Francis,
Elaine McColl, Paul McNamee, Iain R. Chambers, Andreas Unterberg, Dwayne Boyers, and Patrick M. Mitchell 2015;
Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons
License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly credited.
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The main causes of death were the initial head injury (Early Surgery 5 vs. Initial Conservative Treatment 14)
and pneumonia (Early Surgery 4 vs. Initial Conservative Treatment 2). Other causes of death in the Initial
Conservative Treatment group included cachexia (n= 2), ischaemic stroke (n= 2), meningitis (n= 1),
pulmonary embolism (n= 2), renal injury (n= 1), head injury and surgery (n= 1), seizure (n= 1) and
unknown – sudden death in the community (n= 1). In the Early Surgery group, the other causes were
hypovolaemic shock (n= 1), pulmonary embolism (n= 1), head injury and surgery (n= 1) and unknown in
the community (n= 1). Only eight non-death-related major adverse events were recorded (in eight patients):
seizure (n= 3), new/enlarged haematoma (n= 2), infection (n= 2) and other (n= 1).
Table 11 and Figure 8 show the distribution of GOS, GOSE and Rankin Scale at 6 months by treatment
group. For each of these secondary outcomes there is a significant trend towards better outcome in the
Early Surgery group (p= 0.047, 0.052 and 0.043 respectively), although the proportional odds models did
not reach statistical significance (OR 0.67, 95% CI 0.39 to 1.16, p= 0.153; OR 0.66, 95% CI 0.38 to
1.13, p= 0.127; OR 0.67, 95% CI 0.39 to 1.15, p= 0.147).
There were also no significant differences in EQ-5D or limb movements between groups. Of 68 Early
Surgery patients, 20 (29%) reported being employed at 6 months and, of 54 Initial Conservative
Treatment patients, responding to the question 13 (24%) reported being employed.
Subgroup analyses
Prespecified subgroup analyses are shown in Figure 9. None of the subgroups display any significant
heterogeneity of treatment response, although the patients with a GCS of 9–12 had the best response to
Early Surgery.
Outcome by treatment allocation and treatment received
Looking at outcome by allocated and received treatment, 33% (20 out of 61) of patients who were
allocated to Early Surgery and had surgery had died or were severely disabled at 6 months. However, 65%
(20 out of 31) of patients who were allocated to Initial Conservative Treatment and had delayed surgery
had died or were severely disabled at 6 months, compared with 37% (20 out of 54) of the conservative
patients who did not have surgery.
Costs outcome
An unadjusted comparison of raw mean costs showed that Early Surgery was, on average, Int$476 more
costly than Initial Conservative Treatment (Table 12). Generalised linear model (GLM) regression analysis,
adjusting for patient characteristics, showed Early Surgery to be Int$1774 more costly (95% CI –Int$284 to
Int$3831) than Initial Conservative Treatment. Sensitivity analyses showed that overall conclusions were
robust to the choice of regression model for the analysis. Results from subgroup analyses (Table 13) were
highly uncertain based on small sample sizes (and too small to conduct regression analysis) and should
therefore be interpreted with caution.
Patients randomised to the Early Surgery group had an average gain of 0.019 QALYs over a 6-month
period, 95% bootstrapped CI (–0.004 to 0.043), when compared with those randomised to the Initial
Conservative Treatment. This is equivalent to an incremental QALY gain of 3.5 days over a 6-month period.
The broad QALY gains are driven primarily by the increased chance of survival in the Early Surgery group.
A detailed health economic evaluation comparing costs and QALYs has been conducted and is included as
Appendix 4 to this report.
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TABLE 12 Costing analysis (all countries): intention to treat
Cost (Int$)
Early Surgery (n= 82)
Initial Conservative
Treatment (n= 86) Difference of means
Resource use,
mean (SD)
Costs,
mean (SD)
Resource use,
mean (SD)
Costs,
mean (SD)
Raw
difference Adjusted difference
All countries
Cost surgery – 981 (1678) – 515 (1206)
Cost ICU 4.18 (4.20) 2808 (5762) 4.06 (4.61) 2988 (6131)
Cost HDU 1.72 (2.55) 385 (1053) 1.76 (3.01) 461 (1445)
Cost ward 11.88 (15.95) 3595 (10,206) 14.24 (29.43) 3997 (13,789)
Cost
readmission
4.23 (14.43) 1145 (5775) 2.42 (9.63) 421 (1720)
Total cost – 8812 (18,032)a – 8336 (18,685)a 476 GLM model 1774
(95% CI –284 to 3831)
GLM, generalised linear model; HDU, high-dependency unit; ICU, intensive care unit; SD, standard deviation.
a Total mean cost is not equal to the sum of the resource use. This is because of the use of Diagnosis Related Group costs
per episode of care, applied to resource use in Germany.
Reproduced from Mendelow et al.35 © A. David Mendelow, Barbara A. Gregson, Elise N. Rowan, Richard Francis, Elaine McColl,
Paul McNamee, Iain R. Chambers, Andreas Unterberg, Dwayne Boyers, and Patrick M. Mitchell 2015; Published by Mary Ann
Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons License (http://creativecommons.
org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly credited.
TABLE 13 Costing subgroup analysis (by country income subgroup)
Cost (Int$)
Early Surgery (n= 6) Initial Conservative Treatment (n= 10)
Difference
of means
Resource use,
mean (SD)
Costs,
mean (SD)
Resource use,
mean (SD)
Costs,
mean (SD)
Low-income countries
Cost surgery – 142 (0) – 14 (45)
Cost ICU 0.83 (1.60) 203 (391) 1.20 (2.70) 293 (659)
Cost HDU 3.83 (0.75) 468 (92) 3.50 (2.12) 427 (259)
Cost ward 5.33 (1.03) 325 (63) 6.30 (6.43) 384 (392)
Cost
readmission
0 (0.00) 0 (0) 0 (0.00) 0 (0)
Total cost – 1139 (418) – 1118 (614) 20
Cost (Int$)
Early Surgery (n= 40) Initial Conservative Treatment (n= 39)
Difference
of means
Resource use,
mean (SD)
Costs,
mean (SD)
Resource use,
mean (SD)
Costs,
mean (SD)
Lower middle-income countries
Cost surgery – 439 (511) – 176 (369)
Cost ICU 3.20 (3.78) 580 (1449) 2.38 (3.39) 227 (314)
Cost HDU 1.93 (2.84) 87 (128) 1.97 (3.08) 168 (513)
Cost ward 5.70 (5.84) 64 (98) 6.31 (5.29) 125 (364)
Cost
readmission
0.35 (2.21) 3 (20) 0.13 (0.59) 1 (5)
Total cost – 1174 (1583) – 697 (964) 477
continued
DOI: 10.3310/hta19700 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 70
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Gregson et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
33
Cost (Int$)
Early Surgery (n= 28) Initial Conservative Treatment (n= 30)
Difference
of means
Resource use,
mean (SD)
Costs,
mean (SD)
Resource use,
mean (SD)
Costs,
mean (SD)
Upper middle-income countries
Cost surgery – 1089 (1174) – 822 (1031)
Cost ICU 5.43 (3.79) 4272 (4134) 6.93 (4.49) 6010 (5588)
Cost HDU 0.93 (1.84) 643 (1261) 1.17 (3.26) 821 (2295)
Cost ward 16.86 (16.30) 3603 (4132) 14.27 (26.05) 3080 (6267)
Cost
readmission
8.39 (20.55) 997 (2986) 6.23 (15.48) 805 (1881)
Total cost – 10,603 (7517) – 11,538 (10,149) –936
Cost (Int$)
Early Surgery (n= 8) Initial Conservative Treatment (n= 7)
Difference
of means
Resource use,
mean (SD)
Costs,
mean (SD)
Resource use,
mean (SD)
Costs,
mean (SD)
High-income countries
Cost surgery – 4927 (3617) – 2020 (3542)
Cost ICU 7.25 (5.95) 13,432 (14,847) 5.14 (6.72) 10,310 (15,989)
Cost HDU 1.88 (3.18) 1089 (2668) 0.57 (0.98) 622 (964)
Cost ward 30.25 (31.45) 23,671 (24,462) 69.71 (68.18) 34,662 (35,806)
Cost
readmission
12.27 (22.53) 8233 (16,895) 2.29 (6.05) 1719 (4547)
Total cost – 46,489 (38,880)a – 47,483 (46,221)a –994
HDU, high-dependency unit; ICU, intensive care unit; SD, standard deviation.
a Total mean cost is not equal to the sum of the resource use. This is because of the use of Diagnosis Related Group costs
per episode of care, applied to resource use in Germany.
Reproduced from Mendelow et al.35 © A. David Mendelow, Barbara A. Gregson, Elise N. Rowan, Richard Francis,
Elaine McColl, Paul McNamee, Iain R. Chambers, Andreas Unterberg, Dwayne Boyers, and Patrick M. Mitchell 2015;
Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons
License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
in any medium, provided the original work is properly credited.
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Chapter 4 Discussion
The question of whether or not it is beneficial to perform Early Surgery in patients with parenchymal ICHon CT image soon after trauma is one that should be addressed with high priority, as was identified by
NICE in the second edition of its guidelines for head injury.19 The STITCH(TRAUMA) trial was set up and
funded in response to those guideline recommendations. Although the trial was stopped early by the UK
National Institute for Health Research (NIHR) HTA programme, with an associated reduction in statistical
power, there were some clinically significant results. These included a statistically significant survival
advantage (85% vs. 67%) and a non-significant benefit on GOS, both associated with Early Surgery. This
striking reduction in mortality was not accompanied by an increase in severe dependency and there were
no vegetative survivors.
The early management of patients with TICH is not harmonised around the world. The timing of surgery in
patients with parenchymal haematomas after head injury has not been standardised, and therefore no firm
recommendations have been made. This contrasts with patients who develop EDH or acute SDH, because
guidelines based on strong observational data8,9 have recommended early and expeditious scanning and
surgery. Not all TICHs need to be removed, and nor do all the contusions associated with them. Generally,
clinical deterioration and expansion of the haematomas and their associated oedema tend to trigger the
need for surgery. If it were possible to foresee these changes, then secondary brain damage would be
avoided. The objective of the STITCH(TRAUMA) trial was to discover if Early Surgery would prevent the
secondary deterioration so often seen with conservative treatment for these lesions. While the primary
outcome is not statistically significant, there is a strong signal that Early Surgery will indeed prevent such
deterioration and save lives. This is seen in the highly significant reduction in mortality and the better
outcomes in the ordinal analysis of the GOS and Rankin Scale scores. A larger trial is urgently needed to
confirm or refute this signal, which is particularly strong in the patients with a randomisation GCS of 9–12.
The groups of patients with GCS of 9–12 in the STICH and STICH II trials showed a similar trend, and a
meta-analysis of these groups from all three trials shows a large beneficial effect, which is statistically
significant and shows no heterogeneity (Figure 10).
Some units in some countries routinely measure ICP while others do not. The issue of Early Surgery for
TICH is particularly important in those countries that do not measure ICP. This trial was stopped early
by the funding authority because of poor recruitment in the UK, where ICP monitoring is ubiquitous.
Therefore, the trial could not recruit to target and was expected to have a neutral conclusion given the
reduced sample size. However, the evidence suggests that, if the trial had been allowed to continue to
target, a significant difference would have been observed. This would probably be because 86% of
patients were not monitored for ICP either because hospitals did not have the technology available or
because they do not routinely use it for this patient group.34 Unfortunately, despite considerable national
and international efforts, the trial team was not able to secure alternative funding from other sources in
order to continue the trial.
There were crossovers from Initial Conservative Treatment to Early Surgery and vice versa, as occurs in
all surgical trials. This is because surgeons felt compelled to provide rescue surgery to those patients
randomised to Initial Conservative Treatment who later deteriorated. On the other hand, some patients
who were randomised to Early Surgery did not have surgery because their families withdrew consent.
Despite these crossovers, which make the intention-to-treat analysis weaker, the effect of Early Surgery
exceeded 10% and was statistically almost significant. If the total of 840 planned patients had been
recruited, and if the same trend had transpired, this would have been a statistically significant result. In
addition, the patients who had delayed surgery had deteriorated to a much poorer clinical state, and this
was associated with a much poorer outcome (65% dead or severely disabled, compared with only 33% in
those operated upon early).
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Predicting which patients will deteriorate is complex and STICH II identified a small number of patients
(GCS between 9 and 12) who may benefit from such anticipatory treatment.10 In general, SICH patients with
a good prognosis (GCS between 13 and 15) can be safely observed and require craniotomy only if they
deteriorate. This is because there is enough time to perform a craniotomy before other secondary mechanisms
such as brain oedema, mass effect with herniation and reduced CPP from elevated ICP cause harm. The
RESCUEicp trial36,37 has set out to discover if decompressive craniectomy improves outcome in those patients
who have already developed elevated ICP, and recruitment to that trial is now almost complete.
The economic analysis indicates that a strategy of Early Surgery is associated with a small non-significant
increase in health-care costs. Furthermore, patients randomised to the Early Surgery group had an average
gain of 0.019 QALYs over the initial 6-month period when compared with those randomised to the Initial
Conservative Treatment. This is equivalent to an incremental QALY gain of 3.5 days over that period. The
broad QALY gains are driven primarily by the increased chance of survival in the Early Surgery group. Based on
the results of the study, and the WHO guidelines for cost-effectiveness,38 one could interpret the Early Surgery
intervention as offering a high probability of cost-effectiveness in both high- and upper middle-income
countries. There may also be a high probability of cost-effectiveness in lower middle-income countries;
however, based on the cost-effectiveness acceptability curve (CEAC) analysis, this conclusion would be more
sensitive to the threshold value of cost-effectiveness imposed by decision-makers.
Implications for health care
1. There is a strong case for operating on patients with TICH who have a GCS of 9–12. Those who are
alert or just confused (GCS of 13–15) can probably be watched carefully for any deterioration because
there is a safety margin, which diminishes the lower down the GCS the patient descends.
2. Once the GCS has dropped below 8, surgical intervention appears to be less effective.
3. Based on the results of the study, and the WHO guidelines for cost-effectiveness, the Early Surgery
intervention could be interpreted as offering a high probability of cost-effectiveness in both high- and
upper middle-income countries. There may also be a high probability of cost-effectiveness in lower
middle-income countries; however, based on the CEAC analysis, this conclusion would be more
sensitive to the threshold value of cost-effectiveness imposed by decision-makers.
Recommendations for research
This trial has given a very strong signal that Early Surgery is superior to Initial Conservative Treatment for
patients with TICH. This signal was evident despite the sample size being only 20% of that originally
planned. Given that there are 800,000 such injuries each year in the world (8000 per year in the UK
because the UK accounts for 1% of the world’s 7 billion population) the 10.5% absolute improvement in
favourable outcome represents 84,000 patients every year that could have a better outcome. If this is true,
then the trial needs to be repeated with the utmost urgency to avoid this enormous annual excess death
and disability rate that currently prevails for these patients in the UK and everywhere else in the world.
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People’s Republic of China
Beijing, Tiantan Hospital affiliated to Capital Medical University (30) – J Zhao, L Xu, J Li.
Shanghai, Huashan Hospital, Fudan University (9) – Y Sun, J Hu.
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Appendix 1 Consent
Patient information sheet_England_v2.1
Surgical Trial in Traumatic Intracerebral Haemorrhage: 
STITCH (Trauma) 
 
A Study of the Treatment of Brain Haemorrhage 
 
Information for Patients 
 
You are being invited to take part in a research study.  Before you decide it is important for 
you to understand why the research is being done and what it will involve.  Please take time to 
read the following information carefully and discuss it with relatives and friends if you wish.  
Ask us if there is anything that is not clear or if you would like more information.  Take time to 
decide whether or not you wish to take part. 
Thank you for reading this. 
What is the purpose of the study? 
Head injury often causes bruising of the brain where blood leaves the blood vessels and 
enters the brain tissue.  The purpose of this study is to find out if surgical removal of bruised 
areas improves recovery after head injury.  
Surgery carries some risks and would not be considered for small bruises which we know 
recover well.  Larger bruises may have a toxic effect on surrounding un-bruised brain and may 
expand further suggesting that surgical removal can help but we do not know how the risks 
and benefits of surgery are balanced.    
This study is for people with significant bruising of the brain after a head injury. The patients in 
the study will be divided into two groups.  One group will have surgery to remove the blood 
clots and damaged tissue caused by the bruising and the other group will not.  Both groups of 
patients will be carefully monitored.  We will then compare how the two groups recover to see 
if there is any difference. 
Why have I been chosen? 
When someone has a head injury with bruising of the brain, surgeons have to make decisions 
about whether to operate. These decisions can sometimes be complicated.  People with minor 
bruising don’t usually need an operation whereas people with severe bruising do need an 
operation.  In this study we only include people between these two extremes. You have been 
chosen because you have a bruise on the brain caused by a head injury and it is not so small 
that we don’t need to consider an operation and it is not so big that an operation is clearly 
needed.  
Do I have to take part? 
It is up to you to decide whether or not you want to take part. If you do not wish to take part in 
the study your treatment will not be compromised in any way and a decision about the need to 
have an operation will be taken by the Consultant in charge according to how the situation 
develops. If you wish to take part you will be given this information sheet to keep and be 
asked to sign a consent form.  If you decide to take part you are still free to withdraw at any 
time without giving a reason.  This will not affect the standard of care you will receive.  If you 
withdraw from the study we will need to keep all the data collected up to your withdrawal and 
we will ask for permission to send you follow-up questionnaires. 
 
What will happen to me if I take part? 
All the procedures being carried out in this study are part of routine clinical care. If you agree 
to take part in the study you will be randomly allocated, by computer, to one of two groups. 
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One group of patients will receive an immediate operation; the other group of patients will be 
kept under close observation.  If you are in the ‘early operation’ group, your Consultant will 
perform an operation to remove the clot from your brain and closely monitor your condition.  If 
you are in the ‘non-operation’ group, your condition will be closely monitored and you can still 
receive an operation later, should this become necessary.  Whatever group you are allocated 
to you will receive the best available medical treatment which may include the careful 
monitoring of pressure inside your skull. In total we hope to recruit 840 patients to this study. 
What do I have to do? 
Once you have consented to take part in this study details will be collected from your medical 
notes regarding the treatment you receive and your response to that treatment. You will have 
already received a head CT scan before you joined the study as part of your routine care and 
you will be given another head CT scan at around 5 days after your treatment has started so 
that the study research team can analyse the changes after you have received your treatment.  
Sometimes your doctors will need to do further additional CT scans however these ones will 
be for routine clinical reasons.   
At three, six and twelve months after you receive your treatment you and/or your family/carers 
will be sent postal questionnaires asking how you are managing, about your health generally 
and about your use of health services. These questionnaires will each take approximately 15 
minutes to complete and you will be supplied with stamped addressed envelopes to return 
them to the project office in Newcastle.  Before sending the questionnaires we will confirm with 
your consultant and/or GP whether you have experienced any complications and where you 
are living. 
What is the procedure being tested? 
No new procedure is being tested during this study. Both methods of treatment are used 
routinely.   
What are the alternative treatments? 
Early surgery and careful observation/monitoring are the two methods used to treat bruising 
and bleeding in the brain caused by trauma.   
What are the risks or benefits of taking part? 
The usual possible risks associated with having an operation or being monitored in hospital 
apply to this study. Your doctor will be able to discuss these with you. We cannot promise that 
the study will help you, but the information we get might improve treatment of future patients 
with bleeding inside their brain as a result of an injury. 
What if something goes wrong? 
If you participate in this study your hospital consultant remains in charge of your medical care. 
If you wish to complain about any aspect of the way you have been approached or treated 
during the course of this study you should ask to speak to your consultant or local co-ordinator 
who will do his/her best to answer your questions and resolve the situation.  You can also 
contact the STITCH (Trauma) research team in Newcastle by telephoning 0191 222 5764 or 
by writing to: Neurosurgical Trials Unit, 3-4 Claremont Terrace, Newcastle University, 
Newcastle upon Tyne, NE2 4AE, UK.  
 
In the extremely unlikely event that you are harmed by taking part in this research project, 
there are no special compensation arrangements. If you are harmed due to someone’s 
negligence, then you may have grounds for a legal action but you may have to pay for it.  
Regardless of this, if you wish to complain formally about any aspect of the way you have 
been approached or treated during the course of this study, the normal National Health 
Service complaints mechanism is available to you. Details of this can be obtained from your 
local hospital.    
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Will my taking part in this study be kept confidential? 
All information collected about you or from you will be treated as strictly confidential. All the 
data is stored by the co-ordinating centre at Newcastle University. The staff at Newcastle will 
maintain the confidentiality of all the data they store. With your permission they will inform 
your GP that you are taking part in the study.  All data entered on computer for analysis will be 
coded.  The data will be retained for 15 years and then destroyed securely.  Identifiable data 
may be viewed by authorised persons such as researchers, regulatory authorities and 
Newcastle NHS Trust to check the study is being carried out correctly.  All will have a duty of 
confidentiality to you as a research participant and nothing that could reveal your identity will 
be disclosed outside the research site or the Neurosurgical Trials Unit at Newcastle University. 
 
What will happen to the results of the study? 
It is anticipated that the data from this study will be published in medical journals and also by 
the funder of the study. When this happens it will be presented anonymously and it will not be 
possible to identify any individual patient.   
Who is funding and organising this study? 
This study is funded by the NIHR Health Technology Assessment Programme and is being 
carried out in other countries around the world as well as in the UK. The study is being co-
ordinated by the Neurosurgical Trials Unit, Newcastle University.  
 
Who has reviewed this study? 
This study has been reviewed by Southampton and Southwest Hampshire Research Ethics 
Committee A. 
Contact for further details. 
If you have any questions about the study please speak to the Local Co-ordinator 
  
 
 
 
Please retain this sheet for your future information. 
 
 
 
 
Date:  
Protocol STITCH(TRAUMA) Version  
The UK Clinical Research Collaboration has developed a leaflet “Clinical Trials: What they are 
and what they're not” which answers some of the many questions people have about clinical 
trials including: Why do we need to do them? Are they safe? What happens at the end of a 
trial? They have also produced a booklet on "Understanding Clinical Trials", which explains 
what clinical trials are and how and why they are carried out. It is designed to answer the 
many questions people may have when deciding whether to take part in a trial. They are 
available from http://www.ukcrn.org.uk/index/patients/publications or UKCRC, 20 Park 
Crescent, London, W1B 1AL 
Name and contact details of the Local Co-ordinator: 
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Patient Consent Form_England_v2.1
Name of Consultant/Doctor
 
 
I have read and understand the Information Sheet dated __/__/____ 
 (version _ ) for the above study. I have had the opportunity to consider the  
information and any questions I had relating to the study have been answered  
to my satisfaction. 
 
I have discussed the possible beneﬁts and risks to taking part in this research. 
I understand that my participation is voluntary, and that I am free to withdraw at  
any time, without having to give a reason and without my medical care or legal rights  
being affected. 
 
I agree to my General Practitioner being informed that I am participating in the study. 
 
I understand that any personal information collected about me for the trial will be  
treated as strictly conﬁdential, and that my medical records will be consulted and  
data from the study will be published anonymously by the funder and the researchers 
 involved in medical journals and at research meetings. 
 
I understand that relevant sections of my medical notes and data collected during  
the study, may be looked at by individuals from Newcastle University, from regulatory  
authorities or from the NHS Trust, where it is relevant to my taking part in this research.  
I give permission for these individuals to have access to my medical records. 
 
Signature of Patient:   
 
 
Witnessed by: (e.g., Senior Nurse) 
 
 
Position: 
 
 
Date: 
Surgical Trial in Traumatic Intracerebral Haemorrhage: 
STITCH (Trauma) 
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Relative information sheet_England_v3.1
    
Surgical Trial in Traumatic Intracerebral Haemorrhage: 
STITCH (Trauma) 
 
A Study of the Treatment of Brain Haemorrhage 
 
Information for Consultees 
 
Your relative is being invited to take part in a research study.  Before you decide if they would 
wish to take part it is important for you to understand why the research is being done and what 
it will involve.  Please take time to read the following information carefully and discuss it with 
relatives and friends if you wish.  Ask us if there is anything that is not clear or if you would like 
more information.  Take time to decide whether or not your relative would wish to take part. 
Thank you for reading this. 
What is the purpose of the study? 
Head injury often causes bruising of the brain where blood leaves the blood vessels and 
enters the brain tissue.  The purpose of this study is to find out if surgical removal of bruised 
areas improves recovery after head injury.  
Surgery carries some risks and would not be considered for small bruises which we know 
recover well.  Larger bruises may have a toxic effect on surrounding un-bruised brain and may 
expand further suggesting that surgical removal can help but we do not know how the risks 
and benefits of surgery are balanced.    
This study is for people with significant bruising of the brain after a head injury. The patients in 
the study will be divided into two groups.  One group will have surgery to remove the blood 
clots and damaged tissue caused by the bruising and the other group will not.  Both groups of 
patients will be carefully monitored.  We will then compare how the two groups recover to see 
if there is any difference. 
Why has my relative been chosen? 
When someone has a head injury with bruising of the brain, surgeons have to make decisions 
about whether to operate. These decisions can sometimes be complicated.  People with minor 
bruising don’t usually need an operation whereas people with severe bruising do need an 
operation.  In this study we only include people between these two extremes. Your relative 
has been chosen because they have a bruise on the brain caused by a head injury and it is 
not so small that we don’t need to consider an operation and it is not so big that an operation 
is clearly needed.  
Does my relative have to take part? 
It is up to you to decide whether or not your relative would wish to take part. If you do not think 
they would like to take part in the study their treatment will not be compromised in any way 
and a decision about the need to have an operation will be taken by the Consultant in charge 
according to how the situation develops. If you think your relative would be happy to take part 
you will be given this information sheet to keep and be asked to sign a form.  If your relative 
participates in the study they are still free to withdraw at any time without giving a reason.  
This will not affect the standard of care they will receive.  If they withdraw from the study we 
will need to keep all the data collected up to their withdrawal and we will ask for permission to 
send them follow-up questionnaires. 
What will happen to my relative if he/she takes part? 
All the procedures being carried out in this study are part of routine clinical care. If you 
indicate that your relative would wish to take part in the study they will be randomly allocated, 
by computer, to one of two groups. One group of patients will receive an immediate operation; 
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the other group of patients will be kept under close observation.  If they are in the ‘early 
operation’ group, their Consultant will perform an operation to remove the clot from their brain 
and closely monitor their condition.  If your relative is in the ‘non-operation’ group, their 
condition will be closely monitored and they can still receive an operation later, should this 
become necessary.  Whatever group they are allocated to they will receive the best available 
medical treatment which may include the careful monitoring of pressure inside the skull. In 
total we hope to recruit 840 patients to this study. 
What does my relative have to do? 
Once you have indicated that your relative would wish to take part in this study details will be 
collected from their medical notes regarding the treatment they receive and their response to 
that treatment. They will have already received a head CT scan before joining the study as 
part of routine care and they will be given another head CT scan at around 5 days after their 
treatment has started so that the study research team can analyse the changes after they 
have received the treatment.  Sometimes your relative’s doctors will need to do further 
additional CT scans however these ones will be for routine clinical reasons.   
At three, six and twelve months after receiving treatment your relative and/or you and their 
carers will be sent postal questionnaires asking how they are managing, about their health 
generally and about their use of health services. These questionnaires will each take 
approximately 15 minutes to complete and you will be supplied with stamped addressed 
envelopes to return them to the project office in Newcastle.  Before sending the 
questionnaires we will confirm with your relative’s consultant and/or GP whether they have 
experienced any complications and where they are living. 
What is the procedure being tested? 
No new procedure is being tested during this study. Both methods of treatment are used 
routinely.   
What are the alternative treatments? 
Early surgery and careful observation/monitoring are the two methods used to treat bruising 
and bleeding in the brain caused by trauma.   
What are the risks or benefits of taking part? 
The usual possible risks associated with having an operation or being monitored in hospital 
apply to this study. Your relative’s doctor will be able to discuss these with you. We cannot 
promise that the study will help your relative, but the information we get might improve 
treatment of future patients with bleeding inside their brain as a result of an injury. 
What if something goes wrong? 
If your relative participates in this study their hospital consultant remains in charge of their 
medical care. If you wish to complain about any aspect of the way they have been 
approached or treated during the course of this study you should ask to speak to your 
relative’s consultant or the local co-ordinator who will do his/her best to answer your questions 
and resolve the situation.  You can also contact the STITCH (Trauma) research team in 
Newcastle by telephoning 0191 222 5764 or by writing to: Neurosurgical Trials Unit, 3-4 
Claremont Terrace, Newcastle University, Newcastle upon Tyne, NE2 4AE, UK.  
In the extremely unlikely event that your relative is harmed by taking part in this research 
project, there are no special compensation arrangements. If they are harmed due to 
someone’s negligence, then they may have grounds for a legal action but they may have to 
pay for it.  
Regardless of this, if you wish to complain formally about any aspect of the way your relative 
has been approached or treated during the course of this study, the normal National Health 
Service complaints mechanism is available to you. Details of this can be obtained from your 
local hospital.    
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Will my relative’s taking part in this study be kept confidential? 
All information collected about your relative or from you will be treated as strictly confidential. 
All the data is stored by the co-ordinating centre at Newcastle University. The staff at 
Newcastle will maintain the confidentiality of all the data they store. We will inform your 
relative’s GP that they are taking part in the study if you do not think they would object to this.  
All data entered on computer for analysis will be coded.  The data will be retained for 15 years 
and then destroyed securely.  Identifiable data may be viewed by authorised persons such as 
researchers, regulatory authorities and Newcastle NHS Trust to check the study is being 
carried out correctly.  All will have a duty of confidentiality to your relative as a research 
participant and nothing that could reveal their identity will be disclosed outside the research 
site or the Neurosurgical Trials Unit at Newcastle University. 
 
What will happen to the results of the study? 
It is anticipated that the data from this study will be published in medical journals and also by 
the funder of the study. When this happens it will be presented anonymously and it will not be 
possible to identify any individual patient.   
Who is funding and organising this study? 
This study is funded by the NIHR Health Technology Assessment Programme and is being 
carried out in other countries around the world as well as in the UK. The study is being co-
ordinated by the Neurosurgical Trials Unit, Newcastle University.  
Who has reviewed this study? 
This study has been reviewed by Southampton and Southwest Hampshire Research Ethics 
Committee A. 
Contact for further details. 
If you have any questions about the study please speak to the Local Co-ordinator 
  
 
 
 
Please retain this sheet for your future information. 
 
 
 
 
Date:  
Protocol STITCH(TRAUMA) Version  
The UK Clinical Research Collaboration has developed a leaflet “Clinical Trials: What they are 
and what they're not” which answers some of the many questions people have about clinical 
trials including: Why do we need to do them? Are they safe? What happens at the end of a 
trial? They have also produced a booklet on "Understanding Clinical Trials", which explains 
what clinical trials are and how and why they are carried out. It is designed to answer the 
many questions people may have when deciding whether to take part in a trial. They are 
available from http://www.ukcrn.org.uk/index/patients/publications or UKCRC, 20 Park 
Crescent, London, W1B 1AL 
Name and contact details of the Local Co-ordinator: 
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Relative consultation formV2
Name of Consultant/Doctor
I have read and understand the Information Sheet dated __/__/____(version _ ) for the  
above study. I have had the opportunity to consider the information and any questions I had 
relating to the study have been answered to my satisfaction. 
In my opinion he/she would have no objection to taking part in the above study. 
I understand that I can request that he/she is withdrawn from the study at any time,  
without giving a reason and without his/her care or legal rights being affected. 
I conﬁrm that I am not aware that my relative has made any advance directive  
with regard to their care. 
In my opinion my relative would not object to their General Practitioner being informed 
that they are participating in the study. 
I understand that any personal information collected about my relative for the trial will be 
treated as strictly conﬁdential, and that their medical records will be consulted and data  
from the study will be published anonymously by the funder and the researchers involved in 
medical journals and at research meetings. 
I understand that relevant sections of my relative’s medical notes and data collected  
during the study, may be looked at by individuals from Newcastle University, from  
regulatory authorities or from the NHS Trust, where it is relevant to my relative’s taking part in  
this research. In my opinion my relative would not object for these individuals to have access to 
their medical records. 
Signature of relative:   
Name of relative: 
Witnessed by: (e.g., Senior Nurse) 
Position: 
Date: 
Surgical Trial in Traumatic Intracerebral Haemorrhage: 
STITCH (Trauma) 
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Retrospective patient information sheet_England_v1.1
Surgical Trial in Traumatic Intracerebral 
Haemorrhage: STITCH (Trauma) 
 
A Study of the Treatment of Brain Haemorrhage 
 
Information for patients already participating in the study 
 
After discussion between your doctors and your next of kin you were included in a 
research study.  You are being invited to continue to take part in this study.  This 
information sheet explains why the research is being undertaken and what it 
involves.  Please read it carefully and ask questions about anything you do not 
understand.  If you do not have questions now, you may ask later. 
Thank you for reading this. 
What is the purpose of the study? 
Head injury often causes bruising of the brain where blood leaves the blood vessels 
and enters the brain tissue.  The purpose of this study is to ﬁnd out if surgical 
removal of bruised areas improves recovery after head injury.  
Surgery carries some risks and would not be considered for small bruises which we 
know recover well.  Larger bruises may have a toxic effect on surrounding un-bruised 
brain and may expand further suggesting that surgical removal can help but we do 
not know how the risks and beneﬁts of surgery are balanced.    
This study is for people with signiﬁcant bruising of the brain after a head injury. The 
patients in the study will be divided into two groups.  One group will have surgery to 
remove the blood clots and damaged tissue caused by the bruising and the other 
group will not.  Both groups of patients will be carefully monitored.  We will then 
compare how the two groups recover to see if there is any difference. 
Why have I been chosen? 
When someone has a head injury with bruising of the brain, surgeons have to make 
decisions about whether to operate. These decisions can sometimes be complicated.  
People with minor bruising don’t usually need an operation whereas people with 
severe bruising do need an operation.  In this study we only include people between 
these two extremes. You have been chosen because you had a bruise on the brain 
caused by a head injury and it was not so small that we didn’t need to consider an 
operation and it was not so big that an operation was clearly needed.  
Do I have to take part? 
Although your next-of-kin has signed a form indicating that you would wish to take 
part you are still free to withdraw at any time and without giving a reason. If you 
decide to continue taking part you will be given this information sheet to keep and will 
be asked to sign a consent form.  A decision to withdraw at any time will not affect 
the standard of care you will receive.  If you withdraw from the study we will need to 
keep all the data collected up to your withdrawal and we will ask for permission to 
send you follow-up questionnaires. 
What has happened to me? 
All the procedures being carried out in this study are part of routine clinical care.  
After consultation with your relatives, you were entered in this study and randomly 
allocated, by computer, to either receive an immediate operation or careful 
monitoring.   
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If you were allocated to receive an early operation, your consultant will have 
performed surgery to remove the clot from your brain and then continued to closely 
monitor your condition.   
If you were allocated careful monitoring, you will have been kept under close 
observation and you may have received an operation later, if this became necessary.   
Whatever treatment you were allocated to you will have received the best available 
medical care which may have also included careful monitoring of pressure inside 
your skull.  
In total we hope to recruit 840 patients to this study. 
Details will have been collected from your medical notes regarding the treatment you 
received and your response to that treatment. You will have already received a head 
CT scan before you joined the study as part of your routine care and you will have 
another head CT scan at around 5 days after your treatment started so that the study 
research team can analyse the changes after you received treatment.  Sometimes 
your doctors may have needed to do further CT scans for routine clinical reasons.   
What do I have to do? 
At three, six and twelve months after you received your treatment you and/or your 
family/carers will be sent postal questionnaires asking how you are managing, about 
your health generally and about your use of health services. These questionnaires 
will each take approximately 15 minutes to complete and you will be supplied with 
stamped addressed envelopes to return them to the project ofﬁce in Newcastle.  
Before sending the questionnaires we will conﬁrm with your consultant and/or GP 
whether you have experienced any complications and where you are living. 
What are the alternative treatments? 
Early surgery and careful observation/monitoring are the two methods used to treat 
bruising and bleeding in the brain caused by trauma.   
What are the risks or benefits of taking part? 
The usual possible risks associated with having an operation or being monitored in 
hospital apply to this study. Your doctor will be able to discuss these with you. We 
cannot promise that the study will help you, but the information we get might improve 
treatment of future patients with bleeding inside their brain as a result of an injury. 
What if something goes wrong? 
During this study your hospital consultant remains in charge of your medical care. If 
you wish to complain about any aspect of the way you have been approached or 
treated during the course of this study you should ask to speak to your consultant or 
local co-ordinator who will do his/her best to answer your questions and resolve the 
situation.  You can also contact the STITCH (Trauma) research team in Newcastle 
by telephoning 0191 222 5764 or by writing to: Neurosurgical Trials Unit, 3-4 
Claremont Terrace, Newcastle University, Newcastle upon Tyne, NE2 4AE, UK.  
In the extremely unlikely event that you are harmed by taking part in this research 
project, there are no special compensation arrangements. If you are harmed due to 
someone’s negligence, then you may have grounds for a legal action but you may 
have to pay for it.  
Regardless of this, if you wish to complain formally about any aspect of the way you 
have been approached or treated during the course of this study, the normal National 
Health Service complaints mechanism is available to you. Details of this can be 
obtained from your local hospital.    
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All information collected about you or from you will be treated as strictly conﬁdential. 
All the data is stored by the co-ordinating centre at Newcastle University. The staff at 
Newcastle will maintain the conﬁdentiality of all the data they store. With your 
permission they will inform your GP that you are taking part in the study.  All data 
entered on computer for analysis will be coded.  The data will be retained for 15 
years and then destroyed securely.  Identiﬁable data may be viewed by authorised 
persons such as researchers, regulatory authorities and Newcastle NHS Trust to 
check the study is being carried out correctly.  All will have a duty of conﬁdentiality to 
you as a research participant and nothing that could reveal your identity will be 
disclosed outside the research site or the Neurosurgical Trials Unit at Newcastle 
University. 
 
What will happen to the results of the study? 
It is anticipated that the data from this study will be published in medical journals and 
also by the funder of the study. When this happens it will be presented anonymously 
and it will not be possible to identify any individual patient.   
 
Who is funding and organising this study? 
This study is funded by the NIHR Health Technology Assessment Programme and is 
being carried out in other countries around the world as well as in the UK. The study 
is being co-ordinated by the Neurosurgical Trials Unit, Newcastle University.  
 
Who has reviewed this study? 
This study has been reviewed by Southampton and Southwest Hampshire Research 
Ethics Committee A. 
Contact for further details. 
If you have any questions about the study please speak to the Local Co-ordinator. 
  
 
 
 
Please retain this sheet for your future information. 
 
 
 
 
Date:  
Protocol STITCH(TRAUMA) Version  
The UK Clinical Research Collaboration has developed a leaﬂet “Clinical Trials: 
What they are and what they're not” which answers some of the many questions 
people have about clinical trials including: Why do we need to do them? Are they 
safe? What happens at the end of a trial? They have also produced a booklet on 
"Understanding Clinical Trials", which explains what clinical trials are and how and 
why they are carried out. It is designed to answer the many questions people may 
Name and contact details of the Local Co-ordinator: 
Will my taking part in this study be kept confidential?
have when deciding whether to take part in a trial. They are available from 
http://www.ukcrn.org.uk/index/patients/publications or UKCRC, 20 Park Crescent, 
London, W1B 1AL 
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Patient gaining capacity Consent Form _England v1
Name of Consultant/Doctor
I have read and understand the Information Sheet dated __/__/____ 
(version _ ) for the above study. I have had the opportunity to consider the  
information and any questions I had relating to the study have been answered  
to my satisfaction. 
I have discussed the possible beneﬁts and risks to taking part in this research. 
I understand that my participation is voluntary, and that I am free to withdraw at  
any time, without having to give a reason and without my medical care or legal rights  
being affected. 
I agree to my General Practitioner being informed that I am participating in the study. 
I understand that any personal information collected about me for the trial will be  
treated as strictly conﬁdential, and that my medical records will be consulted and  
data from the study will be published anonymously by the funder and the researchers 
involved in medical journals and at research meetings. 
I understand that relevant sections of my medical notes and data collected during  
the study, may be looked at by individuals from Newcastle University, from regulatory  
authorities or from the NHS Trust, where it is relevant to my taking part in this research.  
I give permission for these individuals to have access to my medical records. 
Signature of Patient:   
Witnessed by: (e.g., Senior Nurse) 
Position: 
Date: 
Surgical Trial in Traumatic Intracerebral Haemorrhage: 
STITCH (Trauma) 
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Appendix 2 Data collection forms
Randomisation form
 
Randomisation Form 
 (Please complete prior to randomisation) 
 
1. Country       2. Hospital Name  
3. Centre Number        4. Name of Consultant Neurosurgeon   
5. Patient Initials          
6. Date of Birth (DD/ MM/YYYY):         7     Gender        1 = male, 2 = female 
8. Informed Consent given by     1 = Subject,   2 = proxy, 3 = no consent . .  1 or 2* 
 
Clinical Details 
9. Date of injury   ............................................ (DD/MM/YYYY) 
10.  Time of injury  (24 hour clock)  
  *(Time from injury to randomisation in hours should be < 24 hours) 
 
Record the following details at time of randomisation.  (If patient sedated/ventilated please 
record GCS immediately prior to intubation).        
                 (please use appropriate number score) 
11. Glasgow Coma Score: Best Eye Response (1-4): ......................................... .   
12.                                      Best Verbal Response (1-5): .....................................    
13.                                      Best Motor Response (1-6): (non plegic limb) ..............     
14. Pupils:  1=both reactive, 2=one reactive, 3= both unreactive (< 4mm), 4=both unreactive (≥ 4mm)  
CT Scan: Largest haemorrhage 
15. Location: 1 = frontal, 2 = temporal, 3 = parietal, 4=occipital .  
16. Maximum length of haematoma (mm): .......................... .                 
17. Width of haematoma {at 90 degrees} (mm): . ....        
18. Height of haematoma (mm): ...               
19. Is there a second haemorrhage? 1=yes, 2=no   
  Details of second haemorrhage if applicable 
20. Location: 1 = frontal, 2 = temporal, 3 = parietal, 4=occipital .... 
21. Maximum length of haematoma (mm): .......................... .                
22. Width of haematoma {at 90 degrees} (mm):. ..        
23. Height of haematoma (mm): . ..               
24. Are ALL the other inclusion and exclusion criteria fulfilled?  
No signiﬁcant extradural or subdural haematoma requiring surgery 
No more than two haematomas fulﬁlling inclusion criteria  
There is no severe pre-existing physical or mental disability or comorbidity that would lead to a poor 
 outcome 
 The patient resides in a study country 
The patient, relative or clinician does not have a strong preference for either treatment 
Surgery can be performed within 12 hours of randomisation ..1 = all ticked yes, 2 =any no. .      *All Yes 
 
 
 
                                                     
  
      /     /20 
 
 
} *Total volume of largest haemorrhage = (a x b x c)/2000 
 > 10 ml 
 
      : 
 
 
*Items in green 
italics are 
inclusion criteria 
that must be met
Now with all details ready please telephone for randomisation +44 (0) 1224 551261 
Once the above details have been given the automated system will inform you which treatment arm has been 
allocated to your patient and the randomisation number.  Please enter the randomisation number and the present 
date and time and tick the treatment arm allocated below: 
 
  Randomisation Number                                                Date (DD/MM/YYYY)             /        / 20           Time              
 
  Randomised to:  Early Surgery                                    Initial Conservative Treatment  
 
 S 
 T 
 I 
 T 
 C 
H 
 T 
R 
A 
U 
 M 
A 
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Discharge/2-week follow-up form
 STITCH(Trauma) 2 week form, Version 2 
 
 
 
 
DISCHARGE / 2 WEEK FOLLOW-UP FORM 
                                                                                                         Patient Number                                    
 
This form is to be completed at two weeks post randomisation, or at discharge of the patient from your 
Neurosurgical Centre, whichever is the sooner. Please answer questions, ticking affirmative/filling in appropriate 
boxes. 
                                               
Hospital Name                                                                                            Centre Number   
 
 
Patient Initials                                  Date of Birth (dd/mm/yy):                                   Sex                   f=female, m=male 
 
 
 
         
 
   
 
 
 
 
 
 
 
 
 
                             
 
                                                                                      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                            
       PAGE 1 
 
               /      /       
 S 
 T 
  I 
If patient has died please remember to complete a MAJOR EVENT FORM and return 
this to the STITCH (Trauma) Office. FAX: +44 (0)191 222 5762  
CURRENT STATUS OF PATIENT 
 
Please tick one box and give appropriate date:        
 
 Alive               Dead                   Date of completion of the discharge form                  // 
                                                         (dd/mm/yy)     
 
If alive, status at 2 weeks/ discharge (please tick): 
 
Vegetative               Severely Disabled Moderately Disabled               Good Recovery
                                   (dependent)                               (independent) 
 
Glasgow Coma Score at 2 weeks/ discharge:  
Eye                               1) No eye opening, 2) Opening to pain, 3) Opening to speech, 4) Spontaneous eye opening 
 
Verbal                            1) None, 2) Incomprehensible sounds, 3) Inappropriate words, 4) Confused, 5) Orientated 
 
Motor                             1) No motor response, 2) Extension to pain, 3) Flexion to pain, 4) Withdraws from pain, 
                                              5) Localises to pain, 6) Obeys commands    
 
 
Location of Patient: Please tick one box and fill in the date:     
 
Still in neurosurgical ward...............................................................  
* should be 2 weeks post randomisation 
 
Discharged from hospital................................................................ 
** record discharge address and Tel. No. on contact sheet 
                                                                                                                          
Discharged to (please tick): Rehab unit           Nursing home          Home          
Other           If other, specify_______________________ 
             N/A                       
Transferred from neurosurgical ward to other hospital or ward.                        
***record name of hospital ward, Tel .No. on contact sheet     
 Transferred to (please tick):     General Ward              Other Hospital            
Other                     If other, specify_______________________          
N/A 
If dead please record the date of death (dd/mm/yy)...............................  
Cause of death (please write the most likely number in the box).................   
1 = Head injury/initial injury    2= Head Injury / secondary intracranial damage  
3= Systemic Trauma    4 =Medical Complications  
5= Other 
If other, specify_______________________           
          /             / 
     /       / 
/ /
 T 
 C 
H 
T 
R 
A 
U 
M 
A 
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 STITCH(Trauma) 2 week form, Version 2 
 
                                       
                                                                                                                                                                
                                                                                                                                                               
  Patient Number 
PATIENT DETAILS BEFORE THE HEAD INJURY OCCURRED 
 
Please tick:   
 
Was the patient left or right handed? :            Left                  Right   
 
Primary person that the patient lives with and who can act as a contact/next of kin/carer (please 
choose the lowest most appropriate number to record in the box):    
 
1= Not applicable- lives alone                                      4=siblings      
2=spouse/significant other partner                         5=child/children 
3= parents                                                                    6=other (please specify)____________________________  
 
 
 
SIGNIFICANT MEDICAL HISTORY BEFORE THE INJURY 
 
Please tick yes or no and explain further in the box below: 
   Yes No    Yes No       Yes   No 
 
Cardiovascular                              Endocrine                           Eye, Ear, Nose & Throat            
Gastrointestinal                             Hematologic                       Hepatic           
Musculoskeletal                            Neurologic                          Previous TBI        
Oncologic                                      Pulmonary                           Psychiatric           
Renal                                            Social History                     Developmental History 
Epilepsy                                        Anti-Epileptics   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pre ICH Rankin Score (please write the appropriate number in the box)................................... 
0=Well, no symptoms, 1=Minor symptoms not affecting lifestyle, 2=Minor handicap but independent in self care, 3=Moderate 
handicap, requiring a little help with ADL (Activities Daily Living), 4=Needing a lot of help with ADL, 5=Needing constant attention 
day and night. 
 
 
Pre ICH Mobility (please write appropriate number in the box)..................................................... 
1=Able to walk 200m outside, 2=Able to walk indoors, 3=Unable to walk without help 
 
 
ANTICOAGULANT/ANTITHROMBOTIC TREATMENT AT THE TIME OF THE TRAUMATIC ICH 
 
Was the patient taking/given: 
 
Anticoagulant treatment (e.g. warfarin/heparin)   Yes             No              Initial INR     
 
Antiplatelet therapy (e.g. aspirin/Clopidogrel/Dipyridamole)  Yes             No                    
 
Recent thrombolytic therapy which might have   Yes             No 
contributed to ICH     
  
 
       PAGE 2 
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 STITCH(Trauma) 2 week form, Version 2 
  
 
 
 
  PLEASE COMPLETE FOR ALL PATIENTS                                        Patient Number 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Injuries and Injury Severity:  
Body Region                    Severity 
 
*Please select a number from the list below 
    Surgery Required?  
(Apart from the trial)  Please tick 
    YES NO 
External (skin)    
Head (incl. brain and neck)    
Face    
Chest    
Abdomen/pelvic contents    
Extremities    
Spine    
*0. Not affected      1.Minor: no treatment needed  
2. Moderate: requires only outpatient treatment   3.Serious: requires non-ICU hospital admission  
4. Severe: requires ICU observation and/or basic treatment   
5. Critical: requires intubation, mechanical ventilation or vasopressors for blood pressure support.     
6. Maximal: not survivable. 
 
REFERRAL DETAILS:    
 
     Primary admission*                    Secondary admission** 
 
ARRIVAL AT FIRST HOSPITAL: 
 
 
 
 
 
 
 
ARRIVAL AT STUDY CENTRE: 
 
 
 
Date of arrival first hospital:                    
(dd/mm/yy)                                                        
 
Time of Arrival (24 hour clock):                  
 
Date of arrival study centre:     
(dd/mm/yy) 
 
Time of Arrival (24 hour clock):      
  
       PAGE 3 
        
           /        / 
               :  
          /       / 
               : 
INJURY DETAILS 
 
Date of injury (dd/mm/yy)                                      Time of injury (24 hour clock) 
 
Cause of Injury (please tick): 
Road Traffic Accident                Fall domestic               Fall outside home                Work 
Violence/Assault                       Suicide attempt            Sport/Recreation 
Other (please give details).................................................................................................................................... 
 
If Road Traffic Accident, was the victim (please tick):  
Motor Vehicle Occupant            Pedestrian                   Cyclist                     Moped/Scooter 
Motorbike 
Other (please give details)..................................................................................................................................... 
 
Mechanism of Injury (please tick):         
             Acceleration/Deceleration  
             Direct Impact  
             Crush 
             Blast 
             Penetrating  
             Fall                         Fall – ground floor level 
                                            Fall from height > 1 meter (3ft)  
     
/ /            : 
**Tick here if the patient went to any other 
hospital(s) before arriving at the study centre. 
*Tick here if the 
patient came directly 
to the study centre 
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 STITCH(Trauma) 2 week form, Version 2 
 
 
 
 
                                                                                                                                                  
                                                                                                                                           Patient Number        
   PLEASE COMPLETE FOR ALL PATIENTS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INITIAL NEUROLOGICAL ASSESSMENT  
Was there an initial loss of consciousness? (Please tick): 
 
Yes                    No                  Unknown   
 
  If yes, please give duration* 
 
*1 = < 1 minute 2 = 1 -29 minutes   3 = 30 minutes – 24 hours  4 = > 24 hours  
 
Is there pre traumatic amnesia? (Please tick)  
 
Yes                    No                  Unknown   
 
If yes, please give duration* 
 
*1 = < 1 minute 2 = 1 -29 minutes   3 = 30 minutes – 24 hours  4 = > 24 hours  
 
Is there post traumatic amnesia? (Please tick)  
 
Yes                    No                  Unknown   
 
If yes, please give duration* 
 
*1 = < 1 minute 2 = 1 -29 minutes   3 = 30 minutes – 24 hours  4 = > 24 hours  
 
          
 
       PAGE 4 
        
EMERGENCY SERVICE: THERAPEUTIC PROCEDURES 
 
 
What emergency services were provided for the airway (please tick all that apply):- 
 
No specific treatment                            Oxygen                                      Intubation  
 
 
What secondary insults occurred as a result of the head injury and before the patient was 
randomised to the trial? (Please tick all that apply):  
   Yes No 
Hypoxic                          
Hypotensive                     
Hypothermic                    
Cardiac Arrest 
      IF THIS PATIENT WAS RANDOMISED TO EARLY SURGERY PLEASE GO TO PAGE 5. 
      IF THIS PATIENT WAS RANDOMISED TO INITIAL CONSERVATIVE TREATMENT  
      PLEASE GO TO PAGE 6. 
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 STITCH(Trauma) 2 week form, Version 2 
 
 
                                                                                                                                                              Patient Number 
 
 
       PAGE 5 
        
FOR PATIENTS RANDOMISED TO EARLY SURGERY ONLY 
 
Was early ICH Evacuation performed? Yes  No* 
 
ICH Evacuation performed on: 
 
Date (dd/mm/yy)                                           Time (24 hour clock)  
 
ICH evacuation method (please write appropriate number in box) 
1=craniotomy, 2= other: specify..................................................... 
Was the bone flap replaced?                       Yes              No              
 
Was any other neurosurgical procedure performed? 
 
Yes               No                                Date (dd/mm/yy)  
 
Was any non-cranial surgery performed?    Yes               No 
 
Please give details of the other neurosurgery/non cranial surgery below: 
.............................................................................................................................................................. 
NEUROLOGICAL STATUS IMMEDIATELY PRIOR TO EVACUATION 
 
Patient paralysed and sedated?         Yes                No  
 
Glasgow Coma Score prior to evacuation: 
 
Eye Opening (1-4)                  Best Verbal Response (1-5)               Best Motor Response (1-6)  
 
*If evacuation was NOT done, please record the following details about this decision:  
Reason (please describe briefly below): 
.................................................................................................................................................... 
Date of decision (dd/mm/yy)   Time of decision (24 hour clock)  
 
Glasgow Coma Score when the decision was taken not to evacuate: 
Eye Opening (1-4)                  Best Verbal Response (1-5)               Best Motor Response (1-6)  
 
If evacuation was NOT done was this because of evidence of neuroworsening?*  
 
Yes                No                Date of neuroworsening (dd/mm/yy)   
 
Time of neuroworsening (24 hour clock)  
                                
*Neuroworsening is defined as: 
1. A spontaneous decrease in the Glasgow Coma Scale motor score ≥ 2 points (compared with previous examination), or 
2. A new loss of pupillary reactivity, development or pupillary asymmetry ≥2mm, or 
3. Deterioration in neurological or CT status sufficient to warrant immediate medical or surgical intervention 
 
If there WAS neuroworsening which of the following occurred? (please tick all that apply): 
           Decrease in motor score ≥ 2 points 
          Development of pupillary abnormalities 
          Other neurological and/or CT deterioration 
 
What other action was taken as a result of the neuroworsening? (please tick all that apply): 
           None                  Unscheduled CT scan               Change in medical therapy 
 
PLEASE TURN TO PAGE 7    
/ /             : 
       /       / 
      /       /           : 
*If yes, please complete the top half of 
this page. If no, please give more details 
in the lower half of this page.  
        /        / 
             : 
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 STITCH(Trauma) 2 week form, Version 2 
  
 
                                                                                                                                                                               Patient Number 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
       PAGE 6 
        
FOR PATIENTS RANDOMISED TO CONSERVATIVE TREATMENT ONLY 
 
Was delayed ICH evacuation necessary?       Yes*                 No*        
 
If YES please give date (dd/mm/yy)                                and time (24 clock) 
 
ICH evacuation method (please write appropriate number in box):  
1=craniotomy, 2=other: specify............................................................................................................. 
Was the bone flap replaced?             Yes                        No   
 
Was any other neurosurgical procedure performed? 
 
Yes               No                                Date (dd/mm/yy)  
 
Was any non-cranial surgery performed?    Yes               No 
 
Please give details of the other neurosurgery/non cranial surgery below: 
.............................................................................................................................................................. 
 
NEUROLOGICAL STATUS IMMEDIATELY PRIOR TO EVACUATION 
 
Patient paralysed and sedated?               Yes                    No 
 
Glasgow Coma Score immediately prior to evacuation: 
 
Eye Opening (1-4)                Best Verbal Response (1-5)               Best Motor Response (1-6) 
 
If evacuation WAS done, please record the following additional details about this decision: 
Reason (please describe briefly below): 
.................................................................................................................................................... 
Date of decision (dd/mm/yy)   Time of decision (24 hour clock)  
 
Glasgow Coma Score when the decision was taken to evacuate: 
Eye Opening (1-4)                  Best Verbal Response (1-5)               Best Motor Response (1-6)  
 
If evacuation WAS done was this because of evidence of neuroworsening?* 
 
Yes           No                 Date of neuroworsening (dd/mm/yy)                               
 
Time of neuroworsening (24 hour clock)   
 
*Neuroworsening is defined as: 
1. A spontaneous decrease in the Glasgow Coma Scale motor score ≥ 2 points (compared with the previous examination) 
or 
2. A new loss of pupillary reactivity, development or papillary symmetry ≥2mm, or 
3. Deterioration in neurological or CT status sufficient to warrant immediate medical or surgical intervention 
 
If there WAS neuroworsening which of the following occurred (please tick all that apply): 
          Decrease in motor score ≥ 2 points 
           Development of pupillary abnormalities 
           Other neurological and/or CT deterioration  
 
What other action was taken as a result of the neuroworsening? (please tick all that apply): 
None                   Unscheduled CT scan               Change in medical therapy 
 
PLEASE TURN TO PAGE 7    
/ /            : 
    /      /          
            : 
*If yes, please complete this page. If no, please go 
to the next page. 
/ /
    /      /                     : 
DOI: 10.3310/hta19700 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 70
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Gregson et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
67
 STITCH(Trauma) 2 week form, Version 2 
 
 
MONITORING AND NEUROLOGICAL ASSESSMENT                         Patient Number 
  
 
For all patients at all hospitals please record the following daily from the day before randomisation 
(if available): 
 
(randomisation date=day 0)  Day -1  Day  0  Day 1   Day 2  Day 3  Day 4   Day 5 
Date        
GCS - best eye (1-4)        
GCS - best verbal (1-5)        
GCS - best motor (1-6)        
Affected Arm*         
Affected Leg*         
Speech**         
Pupils***         
Highest temperature (oC)        
Lowest O2 saturation 
(if recorded at your centre) 
       
 
*1=normal, 2= weak, 3= paralysed, 8=dead, 9=alive but cannot assess 
**1= normal, 2=dysphasic, 3=aphasic, 8=dead, 9=alive but cannot assess 
***1= equal and reacting, 2= one eye only reacting, 3=no reaction from either 
 
Is this patient being ICP monitored?                  Yes               No   
 
If yes, please record the following: 
 
What device was used for ICP monitoring? (please tick):  
 
Ventricular 
 
Camino  
 
Codman 
 
Spiegelberg 
 
Rehau-Raumedic 
 
Other (please specify) :_________________________________________________________ 
 
 
Date of implantation of ICP device (dd/mm/yy)                                    Time of implantation (24 hour clock)  
 
 
Date when ICP monitoring ended for this patient (dd/mm/yy)                            Time ended (24 hour clock) 
 
 
Did the ICP/CPP monitoring influence how this patient was managed?    Yes            No    
 
 
 
 
 
 
 
 
 
 
 
       PAGE  7 
       
       PAGE  8 
       /       /       : 
/ /       : 
If yes, please give details about how the ICP or CPP levels changed and what was done as a result: 
     
      If this patient was ICP/CPP monitored, please also complete the form for 
     “Detailed ICP Monitoring” 
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 STITCH(Trauma) 2 week form, Version 2 
 
 
 
                                                                                                                                                         Patient Number 
USE OF HOSPITAL FACILITIES  
 
Please indicate the number of days that the patient was in the following type of hospital wards 
during the first 14 days after randomisation: 
 
Days in an intensive treatment unit (ITU) 
 
Days in a high dependency unit (HDU) 
 
Days in a general neurosurgical ward 
 
Days in other ward, please specify the type of 
ward/facility:______________________________________________________________ 
 
         
POST RANDOMISATION EVENTS (causing clinically significant deterioration) 
 
Please tick appropriate box for each item or code where appropriate: 
                                                                             Yes           No               Date (dd/mm/yy)          Time (24hr clock) 
                                   
Ischaemic Stroke .....       
 
Pulmonary Embolism ......    
(clinically apparent)  
 
Deep Vein Thrombosis .......   
 
Pneumonia ....   
 
Post-Op Intracranial Haemorrhage .......     
(1=EDH, 2=SDH) 
 
Post-Op Infection ...  
(1= wound, 2= septacemia, 3=other) 
 
Epilepsy .. 
 
Other (e.g. CSF, Stroke, MI) please specify  
     
 
Please check that the patient’s scans have been sent to the STITCH Office for detailed 
measurement. 
 
Randomisation CT Scan sent?                                        Yes                      No    
 
5 day post randomisation CT Scan sent?                       Yes                      No 
 
 
Thank you very much for your assistance. 
Please return the completed form and scans to: 
STITCH (Trauma), Neurosurgical Trials Unit, 3-4 Claremont Terrace, 
Newcastle University 
Newcastle upon Tyne 
NE2 4AE, U.K 
FAX: +44 (0)191 222 5762 
       /       /            : 
       /       / 
       /       / 
           : 
           : 
       /       / 
       /       / 
       /       / 
       /       / 
       /       / 
           : 
           : 
           : 
           : 
           : 
       
       PAGE  8 
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Six-month postal follow-up for UK
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Detailed ICP monitoring form
                                                    STITCH (Trauma)  
                     Surgical Trial in Traumatic Intracerebral Haemorrhage 
                                              
                        Detailed ICP Monitoring Record Form 
 
This form is to be completed during the ﬁrst ﬁve days after randomisation in centres who use 
ICP monitoring.  If you are able to send the data electronically by email please do so. If you 
are unable to provide the data electronically then please complete the form.  The form should 
be submitted to the STITCH(Trauma)Ofﬁce along with the Discharge/2 week form. 
 
Hospital Name:                                                                                         Centre Number: 
            
           Patient Number:                                        Patient Date of Birth (dd/mm/yy): 
 
 
DAY MINUS 1 (please note, the date of randomisation is day zero) 
 
Please complete all columns in addition to either MAP or CPP. 
 
Date: (dd/mm/yy):                                 Please tick this box if the patient was not monitored on this day: 
 
 
   
 Time 
   
    Tick if 
      not 
 monitored 
 
     Tick if  
 non Invasive  
  Monitoring 
 
    Tick if  
   Invasive 
 Monitoring 
 
            ICP 
   
      MAP  /  CPP 
(Circle as appropriate) 
 
 
01:00 
02:00 
03:00 
04:00 
05:00 
06:00 
07:00 
08:00 
09:00 
10:00 
11:00 
12:00 
13:00 
14:00 
15:00 
16:00 
17:00 
18:00 
19:00 
20:00 
21:00 
22:00 
23:00 
24:00 
     
  
      /     / 
  /  / 
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 Patient Number:  
 
 
 
 
DAY 0 (please note, the date of randomisation is day zero) 
 
Please complete all columns in addition to either MAP or CPP. 
 
Date: (dd/mm/yy):                                 Please tick this box if the patient was not monitored on this day: 
 
 
 
 
 
Please go to the next page. 
   
 Time 
   
    Tick if 
      not 
 monitored 
 
     Tick if  
 non Invasive  
  Monitoring 
 
    Tick if  
   Invasive 
 Monitoring 
 
            ICP 
   
      MAP  /  CPP 
(Circle as appropriate) 
 
 
01:00 
02:00 
03:00 
04:00 
05:00 
06:00 
07:00 
08:00 
09:00 
10:00 
11:00 
12:00 
13:00 
14:00 
15:00 
16:00 
17:00 
18:00 
19:00 
20:00 
21:00 
22:00 
23:00 
24:00 
     
  /  / 
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Patient Number:  
 
 
DAY 1 (please note, the date of randomisation is day zero) 
 
Please complete all columns in addition to either MAP or CPP. 
 
Date: (dd/mm/yy):                                 Please tick this box if the patient was not monitored on this day: 
 
 
 
 
 
Please go to the next page. 
   
 Time 
   
    Tick if 
      not 
 monitored 
 
     Tick if  
 non Invasive  
  Monitoring 
 
    Tick if  
   Invasive 
 Monitoring 
 
            ICP 
   
      MAP  /  CPP 
(Circle as appropriate) 
 
 
01:00 
02:00 
03:00 
04:00 
05:00 
06:00 
07:00 
08:00 
09:00 
10:00 
11:00 
12:00 
13:00 
14:00 
15:00 
16:00 
17:00 
18:00 
19:00 
20:00 
21:00 
22:00 
23:00 
24:00 
     
     / /
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Patient Number:  
 
 
DAY 2 (please note, the date of randomisation is day zero) 
 
Please complete all columns in addition to either MAP or CPP. 
 
Date: (dd/mm/yy):                                 Please tick this box if the patient was not monitored on this day: 
 
 
 
 
Please go to the next page. 
   
 Time 
   
    Tick if 
      not 
 monitored 
 
     Tick if  
 non Invasive  
  Monitoring 
 
    Tick if  
   Invasive 
 Monitoring 
 
            ICP 
   
      MAP  /  CPP 
(Circle as appropriate) 
 
 
01:00 
02:00 
03:00 
04:00 
05:00 
06:00 
07:00 
08:00 
09:00 
10:00 
11:00 
12:00 
13:00 
14:00 
15:00 
16:00 
17:00 
18:00 
19:00 
20:00 
21:00 
22:00 
23:00 
24:00 
     
  /  / 
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Patient Number:  
 
 
DAY 3 (please note, the date of randomisation is day zero) 
 
Please complete all columns in addition to either MAP or CPP. 
 
Date: (dd/mm/yy):                                 Please tick this box if the patient was not monitored on this day: 
 
 
 
 
 
 
 
Please go to the next page. 
   
 Time 
   
    Tick if 
      not 
 monitored 
 
     Tick if  
 non Invasive  
  Monitoring 
 
    Tick if  
   Invasive 
 Monitoring 
 
            ICP 
   
      MAP  /  CPP 
(Circle as appropriate) 
 
 
01:00 
02:00 
03:00 
04:00 
05:00 
06:00 
07:00 
08:00 
09:00 
10:00 
11:00 
12:00 
13:00 
14:00 
15:00 
16:00 
17:00 
18:00 
19:00 
20:00 
21:00 
22:00 
23:00 
24:00 
     
  /  / 
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Patient Number:  
 
 
DAY 4 (please note, the date of randomisation is day zero) 
 
Please complete all columns in addition to either MAP or CPP. 
 
Date: (dd/mm/yy):                                 Please tick this box if the patient was not monitored on this day: 
 
 
 
 
 
 
 
 
Please go to the next page. 
   
 Time 
   
    Tick if 
      not 
 monitored 
 
     Tick if  
 non Invasive  
  Monitoring 
 
    Tick if  
   Invasive 
 Monitoring 
 
            ICP 
   
      MAP  /  CPP 
(Circle as appropriate) 
 
 
01:00 
02:00 
03:00 
04:00 
05:00 
06:00 
07:00 
08:00 
09:00 
10:00 
11:00 
12:00 
13:00 
14:00 
15:00 
16:00 
17:00 
18:00 
19:00 
20:00 
21:00 
22:00 
23:00 
24:00 
     
/   /
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Patient Number:  
 
 
DAY 5 (please note, the date of randomisation is day zero) 
 
Please complete all columns in addition to either MAP or CPP. 
 
Date: (dd/mm/yy):                                 Please tick this box if the patient was not monitored on this day: 
 
 
 
 
   
 Time 
   
    Tick if 
      not 
 monitored 
 
     Tick if  
 non Invasive  
  Monitoring 
 
    Tick if  
   Invasive 
 Monitoring 
 
            ICP 
   
      MAP  /  CPP 
(Circle as appropriate) 
 
 
01:00 
02:00 
03:00 
04:00 
05:00 
06:00 
07:00 
08:00 
09:00 
10:00 
11:00 
12:00 
13:00 
14:00 
15:00 
16:00 
17:00 
18:00 
19:00 
20:00 
21:00 
22:00 
23:00 
24:00 
     
/   /
Please return this form to: 
 
STITCH (Trauma), Neurosurgical Trials Unit, 3-4 Claremont Terrace, Newcastle University, 
Newcastle upon Tyne, NE2 4AE, UK 
 
FAX: +44 (0) 191 222 5762      Email: trauma.stitch@ncl.ac.uk         TEL: +44 (0) 191 222 5764 
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Major event form
                                                     STITCH (Trauma) 
                    Surgical Trial in Traumatic Intracerebral Haemorrhage  
 
                     
           MAJOR ADVERSE EVENT FORM 
 
 
Hospital Name                                                                               Centre Number 
 
Patient Number  
   
Patient Date of Birth (dd/mm/yy)                                                          If no major adverse events please tick: 
 
MAJOR ADVERSE EVENTS 
 
Please use this form to report any major adverse events which include: 
 
Please tick all that apply: 
                                                                             Please give date of major adverse event:  
a) death 
b) any relevant life threatening event 
c) any relevant permanent of severely disabling event 
d) any event that requires or prolongs hospitalisation  
                                                                                 
Was the major adverse event directly related to: 
  
  Initial ICH        Deterioration       Traumatic ICH Surgery        Other Injury         Other Surgery         Other not related
 
                                                                      
                        
Please provide a description of the major adverse event, treatment and outcome below:                         
 
 
 
 
 
DEATH 
           1) Date of Death (dd/mm/yy)  
2) Post Mortem performed:       Yes                    No           
 
3) State underlying cause of death  
 
4) Additional details .. 
 
Please now categorise the death by writing the most appropriate number in the box* 
 
*1= head injury/initial injury, 2 = head injury/ secondary intracranial damage, 3= systemic trauma, 4= medical complications,  
 5= other. 
 
HOSPITAL READMISSION 
1) Date initially discharged (dd/mm/yy)  
 
2) Date readmitted (dd/mm/yy)  
 
3) Date discharged (dd/mm/yy)                                                         or still an inpatient:  Yes  
 
 
  
                                                                              
       
      /     / 20 
     
                                                                                   
        /       / 20 
 
      /     / 20 
      /     / 20 
     / / 20  
      Please return the completed form to: 
  STITCH (Trauma), Neurosurgical Trials Unit, 3-4 Claremont Terrace, Newcastle University,   
  Newcastle upon Tyne, NE2 4AE, U.K.  
  FAX: +44 (0) 191 222 5762   TEL: +44 (0) 191 222 5764   
 S 
 T 
  I 
 T 
 C 
 T 
R 
 A 
U 
M 
 A 
 
If a post mortem was 
performed send a copy of 
the report to the STITCH 
(Trauma) office. 
 
                                          
 
  H 
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Screening log
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Appendix 3 Template letters
Initial standard general practitioner letter
    
        
 
 
 
 
 
 
 
 
 
 
 
 
Date 
 
Dear  
 
Re: (Patient) 
 
Patient Address:  
 
This letter is to inform you that <patient> (date of birth) has taken part in a research study: STITCH(TRAUMA): 
Surgical Trial in Traumatic Intracerebral Haemorrhage. 
 
<Patient> was admitted to this hospital with a head injury resulting in an intracerebral haemorrhage (ICH). The 
purpose of the study is to determine whether a policy of early surgical evacuation of the haematoma in 
selected patients with traumatic ICH will improve outcome compared to a policy of initial conservative 
treatment.  
 
<He/She> will be followed up by postal questionnaires at 3, 6 and 12 months for this study as well as any 
other follow-ups that are deemed to be required for <his/her> condition. The STITCH (Trauma) co-ordinating 
centre (Newcastle) will contact you prior to follow ups after the head injury to confirm the patient is still, to the 
best of your knowledge, alive and resident at the above address. This is in order to avoid distress by 
attempting to contact families of patients who have died. In the meantime, if you were aware of any serious 
adverse events resulting in death or hospital admission, it would be extremely helpful if you could let us know 
to help us avoid inappropriate follow-up. Serious Adverse Events must be reported according to UK 
regulations and according to MRC guidelines of Good Clinical Practice. The definitions of Serious Adverse 
Events in international clinical trials include the following (regardless of causality): 
 
 Death 
 Life threatening event 
 Event requiring or prolonging hospitalisation 
 Event causing permanent disability 
 
Please find enclosed an information sheet which will give you more information about the study and a Major 
Adverse Event form. 
 
Should you have any questions regarding this study please do not hesitate to contact Professor Mendelow or 
myself at the Directorate of Neurosciences, Newcastle General Hospital. 
 
Yours sincerely  
 
 
 
 
 
 
 
 
Professor A David Mendelow                                                         Dr Barbara A Gregson 
Principal Investigator                                                                      Trial Director    
 
STITCH (Trauma)  
Neurosurgical Trials Unit 
3-4 Claremont Terrace 
Newcastle University 
Newcastle upon Tyne 
NE2 4AE 
DOI: 10.3310/hta19700 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 70
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Gregson et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
111
6-month standard general practitioner letter
       
Dear  
Re:  
Patient Address:  
This letter is to inform you that  was admitted to hospital with a traumatic intracerebral haemorrhage on 18//** 
and agreed to take part in a multicentre study, funded by the MRC, of early surgical treatment. The purpose of 
the study is to determine whether a policy of early surgical evacuation of the haematoma in selected patients 
with traumatic ICH will improve outcome compared to a policy of initial conservative treatment. 
We intend to assess survival and functional outcome at 6 months by a postal questionnaire to the patient or to 
a relative. 
We are now contacting you to conﬁrm that is still, or to the best of your knowledge, alive and resident at the 
above address. This is in order to avoid distress by attempting to contact families of patients who have died. If 
you are aware of any serious adverse events resulting in death or hospital admission, it would be extremely 
helpful if you could let us know to help us avoid inappropriate follow-up. Serious Adverse Events must be 
reported according to UK regulations and according to MRC guidelines of Good Clinical Practice. The 
deﬁnitions of Serious Adverse Events in international clinical trials include the following (regardless of 
causality): 
 Death 
 Life threatening event 
 Event requiring or prolonging hospitalisation 
 Event causing permanent disability 
If you know of any of these occurring since experienced the intracerebral haemorrhage please would you 
complete the enclosed Major Adverse Events form and return it in the enclosed envelope. 
Should you have any questions regarding this study please do not hesitate to contact Professor Mendelow or 
myself at the Neurosurgical Trials Unit. 
Thank you in anticipation of your assistance. 
Yours sincerely  
Professor A David Mendelow                                                         Dr Barbara A Gregson 
Principal Investigator                                                                      Trial Director    
    
STITCH (Trauma)  
Neurosurgical Trials Unit 
3-4 Claremont Terrace 
Newcastle University 
Newcastle upon Tyne 
NE2 4AE 
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Template cover letter to accompany 6-month form
 29 November 2010 
 
 
 
Dear ZZZZZZZ, 
 
When you were in hospital you or your relatives agreed for you to be part of the STITCH (Trauma) 
study which is for people who have had a head injury. As part of the study, we at the Neurosurgical 
Trials Unit contact STITCH (Trauma) patients at three, six and twelve months after their head injury 
to see how they are doing. 
 
We would be grateful if you (or someone on your behalf) could complete the enclosed questionnaire 
and return it using the postal vouchers provided, which can be exchanged at your post office. The 
information from the questionnaire will be used to help us improve the treatment of head injuries and, 
of course, will be confidential. 
 
If you have any problems completing the questionnaire, please contact your local neurosurgeon 
(XXXXXXXXX) at (YYYYYY Hospital, City), and they will be glad to help. 
 
Yours sincerely, 
 
 
 
 
 
 
 
 
Dr B Gregson  
Trial Director 
 
 
Neurosurgical Trials Unit,  
3-4 Claremont Terrace,  
Newcastle University,  
Newcastle upon Tyne,  
NE2 4AE, U.K. 
 
Tel: 0191 222 5793 
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Appendix 4 Health economic analysis
Prepared by Dr Dwayne Boyers and Professor Paul McNamee
Introduction
The objective of the economic evaluation is to assess the cost-effectiveness of a strategy of Early Surgery
compared with Initial Conservative Treatment in the management of traumatic ICH. This chapter reports
the quality of life outcomes, resource use, costs and cost-effectiveness analyses performed alongside the
STITCH(TRAUMA) randomised controlled trial, over a 6-month follow-up period.
It should be noted that the original intention of the economic component of the study was to conduct
a cost–utility analysis from the UK NHS perspective, using cost and outcome data collected only on
UK patients. We anticipated recruiting 150 UK patients into the trial to achieve this goal. However, UK
recruitment achieved only six patients, which was not sufficient to produce a meaningful assessment of
costs and outcomes for UK patients. An alternative analysis was therefore conducted, which used data
from all participating centres in all countries recruiting into the trial. This approach has the advantage of
being more relevant to a wider group of decision-makers. However, such an approach required the
collection of additional cost data in non-UK sites, which proved challenging for some centres. Results are
presented in terms of all patients recruited as a single analysis, as well as subgroup analyses based
on World Bank country income group classifications (low-, lower middle-, upper middle- and
high-income countries).
Methods
Resource use and costs
The main analysis focuses on results from an international perspective. However, given that the original
objective of the cost-effectiveness analysis was to report from a UK perspective, we begin by reporting
UK resource use for the six patients recruited into the trial.
Resource use and costs based on a UK analysis
Descriptive results are presented for the resource use and costs associated with UK participants for
information only. Costs are assigned to resource use data based on 2013 health resource group (HRG)
payment by results data.1 We apply the non-elective cost associated with intracranial procedures for
trauma with a diagnosis of intracranial injury (HRG code AA02).39 Costs with (£6231 up to 43 days
admission+ £207 per day thereafter) and without (£4126 up to 18 days+ £207 per day thereafter)
complications are presented. As our data are presented in days in hospital, we calculate cost per day
as the tariff value, divided through by the trim-point time. We then take the average tariff for those with
and without complications. This means an overall cost per day applied to resource use in the analysis of
£187 per day over the initial episode of care. Further, data from the patient questionnaire are used to
estimate the number and length of hospital readmissions at 6 months’ follow-up. As the exact reason for
readmission was not reported, we have assumed the same HRG codes would apply to these episodes of
care also.
Resource use and costs based on international analysis
All data from the six UK trial participants are used in the costing analysis together with additional data
collected from the other trial participating countries. Collection of this supplementary data required the
development of a site-specific questionnaire, administered to all participating centres in the trial, to collect
data on resource use and unit costs of care. The supplementary questionnaire used for the analysis is
included as Appendix 5. Not all sites responded to this questionnaire which generated a substantial
amount of missing data. Data were returned for 16 out of 31 sites (52%), representing 115 out of
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168 (68%) patients recruited to the study. This required the imputation of cost and resource use data
following some plausible assumptions, namely:
i. Where resource use and cost data were missing for some centres recruiting within a country, we have
imputed weighted averages based on the number of patients recruited at centres where data
are available.
ii. Where resource use and cost data were missing for all centres within a country, we have pragmatically
imputed weighted average data from all countries in the same income group, with country income
subgroups determined according to World Bank classifications.
The impact of these data imputation methods is tested in sensitivity analyses, described in the sensitivity
analyses section of this chapter.
The costing analysis is reported on the intention-to-treat principle and undertaken from an international
health services perspective. The likely major drivers of costs (i.e. surgery, hospital stay and readmissions) are
included. Surgery resource use (including staff time and overheads) and unit costs (e.g. surgeon’s salary and
cost of theatre use) were collected using the site-specific questionnaires. Other health-care resource use
data were collected, including days in intensive care, high-dependency units and general wards (all sourced
from individual case report forms) and hospital readmissions (sourced from the participant 6-month
questionnaire). The analysis follows recommendations from Drummond et al.29 and Manca et al.,30
reporting resource use and cost data at the country level. The costing of these hospital resource use data is
undertaken in two stages. First, we apply country-specific unit costs for nights in hospital (intensive care
unit, high-dependency unit, general ward) to resource use data to generate total costs. National average
unit costs were not available for the majority of countries in the trial. Costs were therefore sourced directly
from finance departments at specific sites and applied to resource use data to generate estimates of costs.
Then, country-specific unit costs were transformed into international dollar costs (2013 values), using the
Campbell & Cochrane Economics Methods Group purchasing power parity calculator.31
To account for the highly skewed nature of cost data (i.e. a small proportion of patients incurring very high
costs), we use GLM regression models, specifying a gamma family and identity link which best fits the
distribution of the cost data. The choice of base-case model for the analysis was made on the basis of
the lowest Akaike information criterion score, a method which is recommended as standard best practice.30
Heteroskedastic robust standard errors were used for all analyses. The model estimates the impact of
treatment group (Early Surgery compared with Initial Conservative Treatment) on costs adjusting for patient
characteristics (age and sex). GLM models were bootstrapped using non-parametric bootstrapping
techniques (n= 1000 repetitions) in Stata Version 13 (StataCorp LP, College Station, TX, USA) to generate
data for developing CEACs.31
Subgroup analyses of costs
Owing to the differences in organisation of care across countries and the value of money differences
across jurisdictions, it is likely that the base-case analysis (a single analysis of all trial participants), while
statistically more efficient, may have little relevance to informing decision-making at an individual country
level. Results are, thus, also reported for groups of countries based on a measure of their development.
For this purpose, all countries within the trial were ranked in ascending order of GNI per capita, according
to World Bank classifications. The classification groups are low income, GNI per capita equal to Int$1005
or less (including Nepal); lower middle income, GNI per capita between Int$1006 and Int$3975 (including
India); upper middle income, GNI per capita between Int$3976 and Int$12,275 (including China); and high
income, GNI per capita of Int$12,276 or more (including most Western European countries). The logic is
that such countries with similar GNI will deliver broadly comparable levels of care and reporting in this way
improves the relevance of the costing for local policy-makers. It also provides an intuitive grouping of
countries in the absence of enough data to conduct a country-specific analysis. This approach has been
used successfully in a previous study.40
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Quality-adjusted life-years
The EQ-5D-3L generic quality of life instrument41 was administered to all trial participants at 6 months’
follow-up. Responses to the EQ-5D-3L questionnaire were valued using UK general population tariffs32
to generate a utility score for every patient within the trial. We assumed that all patients suitable for
randomisation were in an unconscious state and would thus have a baseline utility of –0.402.42 Given a
lack of published tariff data across all trial recruiting countries, we have assumed that the UK tariffs offer
a reasonable reflection of quality of life scores across all trial participants. This assumption is associated
with limitations and assumes preferences for health states valued on the EQ-5D-3L are similar across
countries. However, this approach offered the most pragmatic solution and has the advantage of applying
tariffs derived from a standard method (i.e. time trade-off) to all quality of life data.
Quality-of-life data derived from the EQ-5D-3L are combined with mortality data from the trial, using the
standard assumption that all participants who have died in the trial will have a utility value of 0. QALYs are
then calculated on the basis of these assumptions using an area beneath the curve approach, assuming
linear extrapolation of utility between time points [baseline (assumed –0.402) and 6 months’ follow-up].
Where the date of death was available, the QALY calculation has been modified to include this additional
information. This introduces some asymmetries into the calculation between those who died and those
who survived. The impact of assuming a linear extrapolation between time points for all patients is tested
in the sensitivity analysis.
Differences in QALY estimates across groups are analysed using ordinary least squares (OLSs) standard
linear regression models. Bootstrapped regressions (1000 repetitions in Stata) are conducted to account for
the non-normality of QALY data and regressions are adjusted for patient characteristics, namely age and
sex, and to generate data for CEACs.43 Heteroskedastic robust standard errors are applied to all models.
Subgroup analyses are presented for the utility scores and QALYs for each country income group according
to that outlined in the Subgroup analyses of costs section. This facilitates the production of incremental
cost-effectiveness ratios (ICERs) for each country income group.
Cost–utility analysis
The health economic evaluation is a cost–utility analysis, reporting results as incremental cost per QALY
gained for Early Surgery compared with Initial Conservative Treatment. The cost per QALY is presented
using the ICER, calculated as the coefficient of treatment effect on costs divided by the coefficient of
treatment effect on QALYs from the respective linear regression models. Estimates of the ICER should then
be compared with the normal decision-making practice in individual countries or regions.
Costs and QALY differences are presented on the cost-effectiveness plane and CEACs are derived from the
net benefit statistic to illustrate the probability of Early Surgery being the most cost-effective option. All
statistical analyses were conducted using Stata and Microsoft Excel® (Microsoft Corporation, Redmond,
WA, USA) was used for calculation of CEACs. Owing to the short period of follow-up of only 6 months,
no discounting of costs or QALYs was necessary. No extrapolation to a longer-term time horizon was
conducted. Owing to the acute nature of the clinical indication, and the likely recovery time after surgery,
it is likely that all patients will either have recovered or died during the trial follow-up period, with no
substantial additional costs or QALYs to be accrued over a lifetime horizon.
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Sensitivity analyses and assumptions
Resource use and costs
A range of sensitivity analyses were undertaken in order to test the impact of assumptions and uncertainty
surrounding resource use and cost data. Specifically:
i. We have tested the impact of variability of resource use and costs at different sites within a country. We
conducted an assessment where costs for a given country were estimated on the basis of the highest and
lowest cost sites within a country, with those costs applied to all sites in that country. This analysis helps to
assess the variability in the organisation of care at different sites within a country and will to some extent
address the impact of any differences in the private/public provision of care at different sites.
ii. We have tested the impact of variability of resource use and costs at a regional level, where a region is
defined by the World Bank country income classifications outlined above. The aim of this sensitivity
analysis is to address the uncertainty across countries within an income group and present a plausible
range of costs and ICERs for countries (including those not participating in the trial) at a regional level.
These and other assumptions used for the analysis of cost data are presented in Table 14. The table
outlines the assumptions made together with justifications for each assumption and any sensitivity analyses
conducted to assess the impact on costs and cost-effectiveness.
Quality of life and quality-adjusted life-years
European Quality of Life-5 Dimensions-3 level follow-up responses and death data were fully recorded for
all respondents who entered the trial and therefore QALY data were complete, with no missing data
needing to be imputed. Owing to a large number of deaths within the trial, we have conducted sensitivity
analyses exploring the impact of alternative methods of extrapolation of the EQ-5D-3L utility data for
calculation of QALYs in the trial. The base-case analysis imputes a utility score of ‘0’ from the date of
death to 6-month follow-up for those who died. Survivors’ QALYs are calculated on the basis of linear
interpolation between time points. This reflects the fact that there may, in theory, be a QALY benefit to
dying earlier in the trial, as opposed to remaining in a health state valued worse than death for a longer
period of time. However, the use of these data in this way creates an asymmetry of information between
those who survived and those who died over the trial follow-up, as we have more precise information for
those who died. We, therefore, conducted an alternative analysis, in which all patients accrued QALY gains
using the same linear interpolation, regardless of whether they survived or died. Although this method
addresses the issues of asymmetry in the information available, it does not make use of all information
available to us for QALY calculation. Assumptions surrounding QALY calculations, justifications and
associated sensitivity analyses conducted where appropriate are outlined in Table 15.
Analysis models of data and the impact of crossovers within the trial
In addition to the sensitivity analyses carried out on the resource use, unit cost and QALY calculations
outlined in Tables 14 and 15, we conduct two further sensitivity analyses investigating the impact on results
of (1) using an alternative non-parametric bootstrapped OLS regression model to account for the non-normal
distribution of both cost and QALY data and (2) including interaction terms in the base-case analysis model
to address the impact of crossovers on incremental costs, incremental QALYs and on cost-effectiveness.
Sampling uncertainty
Non-parametric bootstrapping techniques,44 based on 1000 repetitions of the GLM and OLS regressions
were undertaken to determine the cost and QALY differences, respectively, between Early Surgery and
Initial Conservative Treatment. Data from these bootstrapped regressions for cost and QALY differences were
used to develop CEACs and to present scatterplots of cost and QALY differences on the cost-effectiveness
plane.44 CEACs are calculated using a net benefit approach and indicate the probability of an intervention
being cost-effective at various threshold values of willingness to pay (WTP) for a QALY gain. They are
especially useful when making decisions on cost-effectiveness on the balance of probabilities, and when
incremental costs or effects fail to meet the traditional level of statistical significance (i.e. 95% confidence).
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Results
Resource use and costs – site-specific costing questionnaire
Full hospital resource use data were available for all patients within the trial (n= 168). These data were
supplemented by unit cost information and surgical resource use data collected from the additional site
questionnaires. The questionnaires were sent to all 31 recruiting sites in 13 countries worldwide. Data
were returned for 16 out of 31 sites (52%), representing 115 out of 168 (68%) patients recruited to the
study. Completeness of data from the questionnaires is outlined in Figure 11.
Data from the site-specific questionnaires returned were used to make plausible assumptions about
resource use and unit costs in other countries where data were missing. These assumptions and sensitivity
analyses undertaken have been outlined in Table 14.
The results of the surgery costing exercise show wide variation within countries, for example India (Figure 12)
and across countries (Figure 13).
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reported complete surgery costing data.
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Figure 12 shows substantial variation in costs across the two sites which reported data for India. This is
because of different public/private mixes of care at these hospitals and illustrates the impact this variability
can have on the cost estimates at a country level. The variation between sites in India is the most extreme
of all the countries recruiting to the trial; however, it illustrates the need to conduct sensitivity analyses for
the imputation of data at all the other centres who did not contribute data to the resource use and costing
questionnaire. Figure 13 illustrates the variability in costing across countries.
There is wide variability across the different countries recruiting to the trial. As expected, countries in
Europe have much greater treatment costs than those in lower-income countries. However, even within
country income groups, there appears to be substantial variability. The most extreme variation in
country groups is between the UK and the Czech Republic, which again illustrates the importance of
sensitivity analyses to assess the impact of this variation on total cost estimates for the final
cost-effectiveness calculations.
Resource use and costs: – UK analysis
The results of the resource use and costs associated with the six patients recruited from the UK into the
study are presented in Table 16, using descriptive statistics and are presented for information only.
The remainder of this chapter refers to the costing and cost-effectiveness analysis from an international
health-care provider perspective, using data from all participants recruited into the study.
Resource use and costs: international analysis
The results of the base-case costing analysis, showing mean [standard deviation (SD)] resource use and
mean (SD) costs in international dollars, based on the intention-to-treat principle are reported in Table 17.
For the whole sample, a comparison of raw mean costs shows that Early Surgery was, on average,
Int$476 more costly than Initial Conservative Treatment. Using the general linear modelling estimates, with
adjustment for patient characteristics of age and sex, Early Surgery is Int$1774 more costly (95% CI –Int
$132 to Int$3679). The results are not significantly different between groups at the traditional 5% level of
significance, but are significant at the 10% level. This suggests that there is weak evidence which suggests
that Early Surgery is significantly more expensive than Initial Conservative Treatment. This perhaps indicates
that patients, who are more likely to survive in the Early Surgery arm, are thus more likely to incur greater
health-care costs also, through longer term treatment, and rehospitalisations as a result of their survival.
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TABLE 16 UK-specific resource use and cost data (£)
Cost item
Early Surgery,
mean (SD)
resource use
Initial
Conservative
Treatment,
mean (SD)
resource use
Early Surgery,
mean costs per
patient (£)a
Initial
Conservative
Treatment,
mean costs
per patient (£)a
Mean cost
difference
(Early Surgery vs.
Initial
Conservative
Treatment) (£)
n 2 4 2 4 –
Cost surgery – – – – –
Cost ICU 7 (9.9) 3.5 (7) – – –
Cost HDU 3.5 (4.9) 1 (1.5) – – –
Cost ward 28 (24) 49.3 (61) – – –
Cost of initial
episode of care
(without CC –
with CC)
Mean total
days= 38.5
Mean total
days= 53.8
7199.50 10,061 –2861.50
Cost hospital
readmission
(days)
32.5 (46) 4 (8) 6077.50 748 5329.50
Total costs – – 13,277 10,809 2468
CC, complications and comorbidities; HDU, high-dependency unit; ICU, intensive care unit, SD, standard deviation.
a Based on a unit cost per day of £187, calculated as the average of tariffs with and without complications and divided
through by the trim-point times to derive a cost per day.
TABLE 17 Base-case cost analysis (including all sites recruiting to the trial)
Costs (Int$)
Early Surgery (n= 82)
Initial Conservative
Treatment (n= 86) Difference of means
Resource use;
mean (SD)
Costs (Int$);
mean (SD)
Resource use;
mean (SD)
Costs (Int$);
mean (SD)
Raw difference
(Int$)
Adjusted difference
(Int$) (95% CI)
All countries
Cost surgery – 981 (1678) – 515 (1206) 476 1774 (–132 to 3679)
Cost ICU 4.18 (4.2) 2808 (5762) 4.06 (4.61) 2988 (6131)
Cost HDU 1.72 (2.55) 385 (1053) 1.76 (3.01) 461 (1445)
Cost ward 11.88 (15.95) 3595 (10,206) 14.24 (29.43) 3997 (13,789)
Cost
readmission
4.23 (14.43) 1145 (5775) 2.42 (9.63) 421 (1720)
Total cost – 8812 (18,032)a – 8336 (18,685)a
HDU, high-dependency unit; ICU, intensive care unit.
a Total mean cost is not equal to the sum of the resource use. This is because of the use of Diagnosis Related Group costs
per episode of care, applied to resource use in Germany.
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Costing subgroup analysis
Table 18 presents the cost breakdown of resource use and costs by income subgroups based on World
Bank income classifications presented in the Methods section.
Sample sizes were small for country subgroups and results should be interpreted with caution. This is
particularly true for low- and high-income subgroups, which recruited 30 participants. Results should
therefore be treated as exploratory. Owing to the small sample sizes, there is no evidence of significant
differences in costs at the country income subgroup level.
Quality-adjusted life-years
For the purposes of this analysis, we assume that all patients in the trial started with an EQ-5D-3L health
state of unconscious, corresponding to a baseline utility value of –0.402, applied to all patients in the trial.
Figure 14 details the results of the responses to the individual EQ-5D-3L domains at 6 months’ follow-up.
Data are presented on the basis of the percentage of respondents to the questionnaire who reported any
problems on any of the EQ-5D-3L domains, broken down by randomised group.
TABLE 18 Costing subgroup analysis (by country income subgroup)
Costs (Int$)
Early Surgery (n= 6)
Initial Conservative Treatment
(n= 10) Difference of means
Resource use,
mean (SD)
Costs,
mean (SD)
Resource use,
mean (SD)
Costs,
mean (SD)
Raw
difference
Adjusted difference,
(95% CI)a
Low-income countries
Cost surgery – 142 (0) – 14 (45) 20 205 (–48 to 459)
Cost ICU 0.83 (1.60) 203 (391) 1.20 (2.70) 293 (659)
Cost HDU 3.83 (0.75) 468 (92) 3.5 (2.12) 427 (259)
Cost ward 5.33 (1.03) 325 (63) 6.30 (6.43) 384 (392)
Cost
readmission
0.00 (0.00) 0 (0) 0.00 (0.00) 0 (0)
Total cost – 1139 (418) – 1118 (614)
Costs (Int$)
Early Surgery (n= 40)
Initial Conservative Treatment
(n= 39) Difference of means
Resource use,
mean (SD)
Costs,
mean (SD)
Resource use,
mean (SD)
Costs,
mean (SD)
Raw
difference
Adjusted difference,
(95% CI)
Lower middle-income countries
Cost surgery – 439 (511) – 176 (369) 477 192 (–1010 to 395)
Cost ICU 3.20 (3.78) 580 (1449) 2.38 (3.39) 227 (314)
Cost HDU 1.93 (2.84) 87 (128) 1.97 (3.08) 168 (513)
Cost ward 5.70 (5.84) 64 (98) 6.31 (5.29) 125 (364)
Cost
readmission
0.35 (2.21) 3 (20) 0.13 (0.59) 1 (5)
Total cost – 1174 (1583) – 697 (964)
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Costs (Int$)
Early Surgery (n= 28)
Initial Conservative Treatment
(n= 30) Difference of means
Resource use,
mean (SD)
Costs,
mean (SD)
Resource Use,
mean (SD)
Costs,
mean (SD)
Raw
difference
Adjusted difference,
(95% CI)
Upper middle-income countries
Cost surgery – 1089 (1174) – 822 (1031) –936 –1798 (–8378 to 781)
Cost ICU 5.43 (3.79) 4272 (4134) 6.93 (4.49) 6010 (5588)
Cost HDU 0.93 (1.84) 643 (1261) 1.17 (3.26) 821 (2295)
Cost ward 16.86 (16.30) 3603 (4132) 14.27 (26.05) 3080 (6267)
Cost
readmission
8.39 (20.55) 997 (2986) 6.23 (15.48) 805 (1881)
Total cost – 10,603 (7517) – 11,538 (10,149)
Costs (Int$)
Early Surgery (n= 8)
Initial Conservative Treatment
(n= 7) Difference of means
Resource use,
mean (SD)
Costs,
mean (SD)
Resource use,
mean (SD)
Costs,
mean (SD)
Raw
difference
Adjusted difference,
(95% CI)
High-income countries
Cost surgery – 4927 (3,617) – 2020 (3542) –994 –9679
(–41,613 to 22,256)
Cost ICU 7.25 (5.95) 13,432 (14,847) 5.14 (6.72) 10,310 (15,989)
Cost HDU 1.88 (3.18) 1089 (2668) 0.57 (0.98) 622 (964)
Cost ward 30.25 (31.45) 23,671 (24,462) 69.71 (68.18) 34,662 (35,806)
Cost
readmission
12.27 (22.53) 8233 (16,895) 2.29 (6.05) 1719 (4547)
Total cost 46,489 (38,880)b 47,483 (46,221)b
HDU, high-dependency unit; ICU, intensive care unit.
a Mean difference (95% CI) based on GLM regressions with family (gamma), link (Identity).
b Total mean cost is not equal to the sum of the resource use. This is because of the use of Diagnosis Related Group costs
per episode of care, applied to resource use in Germany.
TABLE 18 Costing subgroup analysis (by country income subgroup) (continued)
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FIGURE 14 Responses to the EQ-5D-3L.
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The results show that a greater proportion of respondents in the Early Surgery group experienced at least
some problems in each of the five domains of the EQ-5D-3L, when compared with respondents in the
Initial Conservative Treatment group. The most notable differences were in the Usual Activities, Pain/
Discomfort and Anxiety/Depression domains, in which at least 20% more respondents in the Early Surgery
group had at least some problems. In contrast, the proportion of patients who had died over the course
of the 6-month follow-up period was twice as high in the Initial Conservative Treatment group as in the
Early Surgery group (33% vs. 15% respectively). These data suggest that as more people survive in the Early
Surgery group, they continue to have some problems in their quality of life at 6 months’ follow-up.
Table 19 presents the descriptive statistics for the QALY analysis, based on the assumption of all patients
commencing with a baseline utility score of –0.402, equivalent to being unconscious. Owing to the
non-normal nature of the QALY data, means (SD) are presented together with median (intraquartile range)
for information. Differences between groups are estimated using the bootstrapped regressions described
in the Methods section.
Based on the regression analysis, incorporating date of death into the QALY calculation, and adjusting for
patients’ characteristics of age and sex, we find that on average, patients randomised to the Early Surgery
group had an average gain of 0.019 QALYs over a 6-month period, 95% bootstrapped CI (–0.004
to 0.043), when compared with those randomised to the Initial Conservative Treatment. This is equivalent
to an incremental QALY gain of 3.5 days over a 6-month period. The broad QALY gains are driven
primarily by the increased chance of survival in the Early Surgery group.
TABLE 19 Utility values based on EQ-5D-3L responses
Utility
Early Surgery (n= 82)
Initial Conservative Treatment
(n= 86) Difference of means
Mean (SD) Median (IQR) Mean (SD) Median (IQR)
Raw
difference
Adjusted
differencea
Baseline utilityb –0.402 (0.000) –0.402
(–0.402 to –0.402)
–0.402 (0.000) –0.402
(–0.402 to –0.402)
6-month utility 0.663 (0.374) 0.796
(0.516 to 1.000)
0.530 (0.454) 0.710
(0.000 to 1.000)
QALY
(over 6 months’
follow-up)
0.078 (0.074) 0.0985
(0.0285 to 0.1495)
0.06 (0.085) 0.077
(–0.004 to 0.1495)
0.018 0.019
(95% bootstrapped CI
–0.004 to 0.043)
HDU, high-dependency unit; ICU, intensive care unit; IQR, intraquartile range.
a Mean QALY gain adjusted for patient characteristics of age and sex with 95% bootstrapped CI to account for
non-normality of the QALY data.
b Based on the assumption that all patients attending for care have a baseline utility of –0.402 (i.e. are in an unconscious
state at baseline).
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Subgroup analysis of quality-adjusted life-years data
Again applying UK-specific population weights to the quality of life scores from the EQ-5D-3L
questionnaire, Table 20 presents the results by country income subgroup as classified by the World Bank
country income subgroups described in the Methods section.
For all income subgroups, utility scores were, on average, higher in the Early Surgery group than in the
Initial Conservative Treatment group at 6 months’ follow-up. There were negligible differences in raw
mean QALYs for the low- and high-income countries, although sample sizes were very small and the
regression outputs should be interpreted with caution. However, lower middle- and upper middle-income
countries tended to show average QALY gains for those in the Early Surgery group. The results indicate
that, although not reaching statistically significant QALY gains, patients in these groups are likely to
experience QALY gains from Early Surgery. The results are promising for Early Surgery and indicate broad
generalisability across the largest recruiting countries. Owing to the very small sample sizes recruited, it is
not possible to draw conclusions on QALY outcomes for the low- and high-income countries.
Cost-effectiveness
The results of the base-case cost-effectiveness analysis are presented in Table 21.
For the base-case analysis, the incremental costs for the whole group together were Int$1774, with
average QALY gains of 0.019. Therefore, on this basis, the base-case ICER is Int$1774/0.019= Int$93,368
per QALY gained for Early Surgery when compared with Initial Conservative Treatment.
However, the ICER in itself should be interpreted with caution, given the range of countries which
contributed data to the costing process, and also relating to alternative thresholds of cost-effectiveness
which may be used by decision-makers in different jurisdictions. This complicates interpretation of the ICER.
It may thus be more informative to examine the incremental costs and QALYs for individual subgroups
based on their country income classification. These data are presented in Table 22. Owing to uncertainty in
incremental costs and effects, we have not presented ICERs in this table. Decision-makers are instead
referred to the CEAC presented in Figure 17, which illustrates the uncertainty in cost-effectiveness at the
subgroup level.
TABLE 20 Quality-adjusted life-years and incremental QALYs by country income subgroup
Country
income
group
Early Surgery Initial Conservative Treatment
QALY difference
(95% bootstrap CI)an
Baseline,
mean (SD)
6-month,
mean (SD)
QALY,
mean (SD) n
Baseline,
mean (SD)
6-month,
mean (SD)
QALY,
mean (SD)
All
countries
82 –0.402 (0) 0.663
(0.374)
0.078
(0.074)
86 –0.402 (0) 0.53
(0.454)
0.06
(0.085)
0.019
(–0.004 to 0.043)
Low
income
6 –0.402 (0) 0.918
(0.094)
0.129
(0.023)
10 –0.402 (0) 0.876
(0.331)
0.129
(0.051)
–0.018
(–0.055 to 0.019)
Lower
middle
income
40 –0.402 (0) 0.658
(0.369)
0.082
(0.062)
39 –0.402 (0) 0.548
(0.453)
0.069
(0.075)
0.015
(–0.014 to 0.045)
Upper
middle
income
28 –0.402 (0) 0.630
(0.369)
0.07
(0.074)
30 –0.402 (0) 0.391
(0.460)
0.029
(0.094)
0.037
(–0.006 to 0.08)
High
income
8 –0.402 (0) 0.606
(0.514)
0.051
(0.129)
7 –0.402 (0) 0.575
(0.378)
0.052
(0.081)
0.008
(–0.283 to 0.299)
a Mean differences between arms for QALY calculations based on OLS regression models adjusted for patient
characteristics (age and sex) and presented alongside 95% bootstrapped CIs.
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As expected, there are substantial differences in costs across the subgroups. It appears that incremental
costs of Early Surgery versus Initial Conservative Treatment could be decreasing for more developed
countries. However, the results could equally be skewed by outliers in the data, which would have a large
impact, given the small numbers. Despite substantial uncertainty in the presented results at a subgroup
level, the data, on balance, suggest that favourable results could be achieved for Early Surgery in all
subgroups with the exception of low-income countries.
Sensitivity analyses
A range of sensitivity analyses were undertaken focusing on the assumptions used to impute data from the
site-specific questionnaire, QALY calculation methods and methods of analysis of the data. The impact of
these analyses on cost-effectiveness results is outlined in Table 23. Sensitivity analyses on cost and QALY
calculations are based on the assumptions outlined in the methods section and cross-referenced in the
table below. Further analyses explore the impact of the model of analysis of cost data and the impact of
crossovers within the study. Two ICERs are produced for each sensitivity analysis, the first based on a
comparison of raw mean data across groups and the second based on the incremental costs and QALYs
calculated using regression analyses described.
Owing to the small sample size in two of the income subgroups, sensitivity analyses are performed only on
the whole sample of patients recruited into the trial.
TABLE 21 Base-case cost-effectiveness results
Base case result
Early Surgery,
mean (SD)
Initial Conservative
Treatment, mean (SD)
Difference of means
Raw difference
Adjusted difference
(95% CI)a
Costs (Int$) 8812 (18,032) 8336 (18,685) 476 1774 (–132 to 3679)
QALYs 0.078 (0.074) 0.060 (0.085) 0.018 0.019 (–0.004 to 0.043)
ICER (Int$) – – 26,444 93,368
a Adjusted differences based on the above described GLM model for costs and OLS model for QALYs.
TABLE 22 Cost-effectiveness analysis by subgroup of the population
Country group
Early Surgery
costs (Int$)
Initial
Conservative
Treatment
costs (Int$)
Incremental
costsa (Int$)
Early
Surgery
QALYs (Int$)
Initial
Conservative
Treatment
QALYs (Int$)
Incremental
QALYsa (Int$)
Base-case
analysis
8812 8336 1774 0.078 0.06 0.019
Low income 1139 1118 205 0.129 0.129 –0.018
Lower middle
income
1174 697 192 0.082 0.069 0.015
Upper middle
income
10,603 11,538 –1798 0.070 0.029 0.037
High income 46,489 47,483 –9679 0.051 0.052 0.008
a Based on GLM and OLS regressions for costs and QALYs respectively, with adjustment for patient characteristics of age
and sex.
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The results of the sensitivity analyses show some important impacts on cost-effectiveness calculations
depending on the assumptions used in the analysis. For the costing assumptions, as expected, imputing
higher cost estimates increased the ICERs, and lower cost estimates reduced the ICER. Based on the range
of cost imputations tested in the sensitivity analyses, the ICER ranged from Int$15,227 to Int$141,724. This
serves to illustrate the impact of within-country variation in reported unit costs and resource use from the
centre-specific questionnaires, and the impact of assumptions around missing data on cost estimates used
for the cost-effectiveness analysis. This variation is probably driven by the differing public/private mix of
care in specific countries, and especially in relation to data provided for India. The results were less
sensitive to cross-country variation, within World Bank country income groups. This adds some confidence
to the reliability of cross-country comparisons within income subgroups and suggests results may to some
extent be generalisable to other countries within income groups.
The sensitivity analysis with one of the greatest impacts on the ICER related to the method of QALY
calculation. The base-case analysis makes use of all available information, imputing a utility score of ‘0’ for
those who have died, from the date of death to the end of follow-up. We chose to use the date of death
for QALY estimation because, given the initial negative utility, patients could in theory attain a QALY
advantage from dying earlier in the follow-up period. However, the use of date of death will create an
asymmetry of information on the time point at which utility is accrued in the trial between those who have
died and those who survived, as we have no comparable information for survivors, other than at their
6-month follow up. Therefore, in order to illustrate the impact of this asymmetry, we have conducted an
analysis assuming a linear interpolation between time points when calculating QALYs. This effectively
ignores the date of death in the calculations but addresses the asymmetry of information. Take, for
example, a patient who died at 10 days after surgery. In the base-case analysis, they would have
[(–0.402+ 0)/2] × (10/365)]= –0.005507 QALY, over the first 10 days+ 0 QALYs between death and
6 months. For the sensitivity analysis, the equivalent calculation would be –0.1005 QALYs [(–0.402+ 0)/2] ×
(182.5/365)]. These results show substantial differences in QALY calculation depending on whether or not
date of death is accounted for.
In addition to the base-case GLM model, we conducted exploratory analysis on the impact of model of
analysis on trial outcomes. For example, running a bootstrapped OLS regression model to account for the
skewed distribution of the cost data shows Early Surgery being Int$314 more costly [95% bootstrapped CI
(–Int$5139 to Int$5766)]. The resultant ICER falls to Int$16,526 per QALY gained. However, this analysis
should only be interpreted as exploratory and closer examination of the data confirms that the GLM model
with gamma distribution is the most appropriate fit to the data. However, the analysis serves to illustrate
the potential uncertainty and impact of analysis model on the costing results.
Running an alternative model as a sensitivity analysis, which includes interaction terms to address
crossovers in the GLM model, suggests on average higher costs and lower quality of life for groups which
have crossed over in both directions, therefore indicating that crossovers have an important impact on
results. Increases in costs and deterioration in QALYs were significant at the 10% and 5% levels
respectively for crossovers from initial conservative management to surgery. These results would be
expected, given that crossovers to surgery were likely a result of emergency circumstances. In the model
which adjusts for crossovers, being randomised to Early Surgery, and receiving the randomised allocation
suggests incremental costs of Int$1021 (95% CI –Int$367 to Int$2368) compared with being randomised
to and receiving conservative management.
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Sampling uncertainty
In order to address sampling uncertainty in our estimates, we present the bootstrapped iterations of
incremental costs and incremental outcomes on a scatterplot of the cost-effectiveness plane. These are
also presented in the form of a CEAC, outlining the probability of Early Surgery intervention being a
cost-effective use of scarce health-care resource use. Figures 15 and 16 illustrate the probability of
cost-effectiveness for the base-case analysis.
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FIGURE 15 Scatterplot of the cost-effectiveness plane: Early Surgery vs. Initial Conservative Treatment
(all randomised patients – all countries). ES, Early Surgery; ICT, Initial Conservative Treatment.
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FIGURE 16 Cost-effectiveness acceptability curve: base-case analysis. ES, Early Surgery; ICT, Initial
Conservative Treatment.
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The graphical illustrations presented above indicate the probability of cost-effectiveness of Early Surgery
compared with Initial Conservative Treatment and illustrate the sampling uncertainty surrounding the
cost-effectiveness calculations. The scatterplot shows that there is a high probability of Early Surgery
delivering improved QALYs; however, there is much uncertainty surrounding the incremental cost
estimates. Figure 16 shows the probability of Early Surgery being cost-effective at certain threshold values
of WTP for a QALY gain. The probability of cost-effectiveness increases as WTP increases, indicating
approximately 50% probability of cost-effectiveness at a threshold value of WTP for a QALY gain of Int
$50,000, increasing to approximately 65% when the threshold increases to Int$100,000. However, this
graph should be interpreted with caution. Conclusions on cost-effectiveness would depend on a number
of issues, including (1) how reflective these costs, which are based on all recruiting countries, are of
individual country circumstances and (2) what amount of money decision-makers are willing to pay in
international dollars for a QALY gain in their country. In the light of these two issues, Figure 17 presents
the CEACs calculated for each of the individual income subgroups recruiting into the trial and may be
more informative at a local decision-making level.
The data broken down by subgroup and presented above indicate wide variation in the probability of
cost-effectiveness depending on the country income subgroup considered. The probability of cost-effectiveness
appears to be lowest for the low-income country group. However, data for both low- and high-income groups
are based on very small numbers recruited and are as such unreliable to draw firm conclusions. Higher-income
(e.g. UK, Germany), upper middle-income (e.g. China) and lower middle-income (e.g. India) countries have a
probability of cost-effectiveness between 70% and 80% at a Int$50,000 threshold value of WTP for a
QALY gain.
Interpretation of these country income subgroup CEACs is likely to depend on the wealth of individual
countries and countries in income subgroups here should draw conclusions based on the data presented
for their income subgroup but also in conjunction with normal threshold values of WTP for a QALY in their
jurisdiction. The WHO Choosing Interventions that are Cost-Effective (CHOICE) project has issued guidance
to assist with this process, suggesting that an ICER less than three times gross domestic product (GDP) per
capita might be considered cost-effective and an ICER that is less than GDP per capita would be
considered highly cost-effective.
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FIGURE 17 Cost-effectiveness acceptability curves for base-case and country income subgroups. ES, Early Surgery;
ICT, Initial Conservative Treatment.
APPENDIX 4
NIHR Journals Library www.journalslibrary.nihr.ac.uk
132
Discussion
Our analysis is undertaken from an international health services perspective, with costs and QALYs
presented by country income subgroup, according to World Bank classifications. Our analysis follows a
similar approach to one previously used to report international data in major surgery trials.28 Our results
suggest that an improvement in average QALY outcomes may be achievable for additional costs of Early
Surgery, with many of the QALY analyses falling just short of statistical significance at the 5% level.
However, in one sensitivity analysis which varied the QALY calculation method, incremental QALYs were
significant, highlighting the importance of how the date of death is treated within the calculations. In
terms of costs, there were no significant differences between groups. The results are promising for the
potential cost-effectiveness of Early Surgery and further studies are warranted to confirm these findings.
These results indicate that, had the trial recruited to its original target, there is a high probability that we
would see significant improvements in QALYs associated with Early Surgery.
The results of the analyses and the probability of cost-effectiveness are probably best interpreted on the
income subgroup level. Although the subgroup analyses lack any statistical power, they are perhaps more
relevant to decision-makers locally. The probability of cost-effectiveness at alternative threshold values of
WTP for a QALY gain should be interpreted in the light of guidelines for cost-effectiveness in individual
countries. Not all countries will have formal cost-effectiveness criteria for deciding on best practice
guidelines. However, some studies7 have determined threshold values of WTP for a QALY gain. In addition,
the WHO has suggested three levels of cost-effectiveness based on GDP per capita in that country.
According to these guidelines, interventions could be considered cost-effective if their cost is <GDP per
capita (very cost-effective); 1–3 times GDP per capita (cost-effective); > 3 times GDP per capita (not
cost-effective).38 The thresholds for 2013 could be calculated for any individual country in the trial,
based on data from the World Bank, GDP per capita 2012 international dollars.28 The threshold for
each income country subgroup could be taken as the average of the GDP per capita in all of the trial
participating countries in that country group. On this basis, the thresholds for low-income countries
would be Int$1457 (very cost-effective) and Int$4371 (cost-effective); for lower middle-income countries
Int$4389 (very cost-effective) and Int$13,167 (cost-effective); for upper middle-income countries
Int$14,763 (very cost-effective) and Int$44,289 (cost-effective); and for high-income countries Int$32,363
(very cost-effective) and Int$97,089 (cost-effective).
This assessment of threshold values is designed to be a broad indicator of cost-effectiveness for individual
countries and is based on the assumption that WTP for a QALY gain and WTP to avert a disability-adjusted
life-year loss would be similar. This of course is an assumption which may not fall true in reality given the
different make-up of the measures. However, while they are not identical, they have many similarities in
their composition and could offer a broad estimate of the value placed on health in individual countries
which may not have any formal measure of deciding on cost-effectiveness.
Based on the results of the study, and the WHO guidelines for cost-effectiveness,38 one could interpret
the Early Surgery intervention as offering a high probability of cost-effectiveness in both high- and
upper middle-income countries. There may also be a high probability of cost-effectiveness in lower
middle-income countries also; however, based on the CEAC analysis, this conclusion would be more
sensitive to the threshold value of cost-effectiveness imposed by decision-makers.
The results are based on a number of assumptions which have the potential to greatly influence the
final cost-effectiveness results, as is evident from our sensitivity analyses. The data should therefore be
interpreted as a preliminary indication of cost-effectiveness, based on currently available evidence. A larger
trial population would provide more robust evidence.
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Conclusions
The cost-effectiveness analysis indicates that Early Surgery may be associated with additional QALYs and
increases in health-care expenditures. However, differences in costs and QALYs do not reach statistical
significance. The results of our analyses, especially in relation to costs, should be interpreted with caution,
in light of the assumptions outlined in this chapter. Further research is required to determine more
conclusively whether Early Surgery is more cost-effective than Initial Conservative Treatment.
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Appendix 5 Supplementary Costing Questionnaire
SUPPLEMENTARY COSTING QUESTIONNAIRE
Costing Questionnaire
In the following questionnaire, we are interested in the resource use which would 
typically be required in the delivery of ICH evacuation surgery in the STITCH (Trauma) 
trial.  We are interested in two main areas:
(i) Which staff are involved in providing ICH evacuation surgery (e.g. surgeon, 
anaesthetist, Nurse) and the costs of their time;
(ii) The cost of care in various departments throughout the hospital where the 
patient may be treated for traumatic brain injury (e.g. Intensive Treatment 
Units / High Dependency Units / Neurosurgical wards).
It is likely that the clinician responsible for performing surgery as part of the trial will 
need to fill in the staff requirement sections of this form (Blue colouring).  Please consider 
the requirements for an average, typical procedure.  If you are unsure, or if the 
procedure is dependent on individual circumstances, please give a range of requirements 
as you see fit.  Please remember to include all staff which would be involved in the 
procedure. 
For resource costing questions, it may be that your individual hospital’s financing 
department will need to provide further information (questions highlighted in Green).
We are looking for as much detail as possible, so please append any additional 
information to this document which you feel may help us to develop an accurate measure 
of costing for the STITCH (Trauma) trial.
We are very grateful for your time and efforts in helping us deliver a robust and 
internationally valid health economic assessment of the STITCH (Trauma) trial.
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Clinician to fill in
(BLUE):
Finance department to fill in (GREEN):
QUESTION 1:
Please tell us about ALL members of staff involved in delivering a typical ICH evacuation 
surgery at your hospital (please also indicate how many staff would normally be present in 
the operating theatre, e.g. if 1 consultant surgeon present for 3.5 hours, please enter Surgeon, 
Consultant, 1, 3 hours in the boxes below):
Staff 
member
(e.g. 
surgeon)
Staff
Grade 
(e.g. 
consultant)
Number 
of staff 
present? 
(e.g. 1)
Length of time 
(hrs: mins) of
involvement? 
(e.g. 3 hours : 
30mins)
Pay rate 
(in your 
local 
currency)
Period of time 
pay scale refers 
to
(e.g. per hour / 
week / year etc)
Please indicate how long the following ICH evacuation 
procedures would take (time in theatre):
Minimally Invasive
Craniotomy
Craniectomy
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QUESTION 2:
This section relates to the cost of providing care in various departments throughout your 
hospital.  
2.A  Are you aware of any national unit cost / tariff  
data for your country?
Yes No
If yes, please specify a website or reference   
where this information is available
2.B.  Please indicate the costs of the following types of care in your hospital.  We are 
interested in cost per unit of time. (E.g. cost per hour in a recovery room or cost per night on a 
neurosurgical ward).  If information per unit of time is not available, please indicate a cost per 
procedure of cost per patient and detail your unit in the table below.
Cost in your 
hospital (in local 
currency)
Please indicate unit (e.g. cost per 
hour or cost per day / night etc.)
Theatre costs
Recovery room costs
Intensive care unit costs
High Dependency Unit costs
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Neurosurgical ward costs
General surgical ward costs
General medical ward costs
Other costs (please give details)
General anesthesia
Please give details about any other costs which you feel may be relevant, including sources 
where appropriate. 
Thank you very much for your assistance.
Please return the completed form to:
STITCH (Trauma), Neurosurgical Trials Unit, 3-4 Claremont Terrace, Newcastle University, 
Newcastle upon Tyne, NE2 4AE, U.K.
FAX: +44 (0)191 222 5762
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